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Abstract 
Cognitive impairment is a common non-motor symptom of Parkinson’s disease (PD), but 
the nature of cognitive changes varies considerably between individuals. According to the dual-
syndrome hypothesis, one cluster of patients is characterized by deficits in executive function that 
may be related to fronto-striatal dysfunction. Other patients primarily show non-frontal cognitive 
impairments that progress rapidly to PD dementia (PDD). We provide a comprehensive review of 
event-related potential (ERP) studies to identify ERP measures substantiating the heterogeneity 
of cognitive impairment in PD. Our review revealed evidence for P3b and mismatch-negativity 
alterations in PDD, but not in non-demented PD, indicating that alterations of these ERPs 
constitute electrophysiological markers for PDD. In contrast, ERP correlates of executive 
functions, such as NoGo-P3, N2, and error(-related) negativity (Ne/ERN), appear to be attenuated 
in non-demented PD patients in a dopamine-dependent manner. Hence, ERP measures confirm 
and yield distinct electrophysiological markers for the heterogeneity of cognitive impairment in 
PD. We discuss limitations and open questions of the ERP approach and provide directions and 
predictions for future ERP research. 
Keywords: Parkinson’s disease, Cognition, Dementia, Executive function, Basal ganglia, 
Dopamine, Event-related potentials (ERPs), P3, P3a, P3b, MMN, NoGo-P3, N2, Ne/ERN 
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1 Introduction 
Event-related potentials (ERPs) represent neural activities that are gained from the scalp-
recorded electroencephalogram (EEG) (Luck, 2014). ERPs are usually calculated by averaging 
EEG activity that is time-locked to the occurrence of an observable event, e.g., a sensory stimulus 
(i.e., stimulus-locked ERP), or the onset of a motor reaction (i.e., response-locked ERP). ERPs 
are thought to reflect the summation of postsynaptic potentials of large ensembles of 
synchronously active pyramidal neurons in the cerebral cortex (Woodman, 2010). Distinct 
waveforms of the ERP are characterized by their polarity, scalp distribution, latency, and by their 
sensitivity to particular experimental manipulations. These fluctuations can be conceived of as 
neural correlates of information processing (Duncan et al., 2009). ERP measurements have an 
excellent temporal resolution that allows for the investigation of cognitive processes that occur in 
rapid succession. In addition, ERPs also provide a non-invasive tool also for the assessment of 
disease-related changes in brain functioning (e.g., Duncan et al., 2009; Verleger, 2003). 
ERP latencies are related to the time course of cognitive processes, such as the evaluation 
of a stimulus and the selection and preparation of an appropriate response. ERP amplitudes are 
considered to indicate the extent to which neural resources are allocated to these processes. The 
measurement of ERP latencies and/or amplitudes can thus provide valuable diagnostic 
information about cognitive and neural functions and dysfunctions, over and above behavioral 
performance measures (Duncan et al., 2009). 
The present work presents an overview of the literature concerning ERP correlates of 
cognitive dysfunction and decline in idiopathic Parkinson’s disease (PD). In the following 
sections, we will briefly review the cognitive impairment in PD, and we will introduce the most 
common and important ERPs related to cognitive functions in general and executive control in 
particular. Our focus is on four major cognitive ERP waveforms: mismatch negativity (MMN), 
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P3, N2, and error(-related) negativity (Ne/ERN). All these ERPs have been well characterized in 
terms of their eliciting events, and they have been related to quite specific cognitive processes 
and/or functional neural networks. 
1.1 Cognition in Parkinson’s disease  
PD is one of the most common neurodegenerative disorders, with an incidence of 8–18 
per 100,000 person-years (de Lau and Breteler, 2006). The prime characteristic of PD at the time 
of clinical diagnosis is degeneration of dopaminergic neurons in the substantia nigra pars 
compacta, which results in a depletion of dopamine in the basal ganglia. The cardinal motor 
symptoms of PD are bradykinesia, resting tremor, rigidity, and postural instability. However, PD 
is a multisystem neurodegenerative disorder. Namely, the intracerebral formation of Lewy bodies 
begins at defined anatomical brain sites and advances in a topographically predictable sequence. 
During pre-clinical stages, pathology is confined to the medulla oblongata/pontine tegmentum 
and olfactory bulb/anterior olfactory nucleus. In early symptomatic stages, the substantia nigra 
becomes the focus of pathological changes, whereas in the end-stages of the disease, the Lewy-
related pathological processes enter the neocortex, and the disease manifests itself in all of its 
clinical dimensions (Braak and Del Tredici, 2008; Hawkes et al., 2010). 
In addition to the motor symptoms, the course of neuropathological alterations in PD is 
associated with specific cognitive dysfunction and cognitive decline. In early clinical stages, 
cognitive dysfunction may be mainly attributed to the disruption of dopaminergic signaling in 
fronto-striatal loops, whereas the progression of the disease to its end stages may lead to 
Parkinson’s disease dementia (PDD) in up to 90% of the patients with PD (Gratwicke et al., 
2015). Furthermore, it appears that the patterns of cognitive impairment in PD are heterogeneous 
in nature (Miller et al., 2013), which has led to the proposition of two clusters of PD patients. 
According to this ‘dual-syndrome hypothesis’ (Kehagia et al., 2013; Robbins and Cools, 2014), 
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one cluster is formed by non-demented PD patients with mild cognitive impairment who show 
deficits in tests of planning, task switching, inhibition, conflict processing, phonemic fluency, 
working memory, and feedback-based learning. This pattern of deficits in executive function 
likely reflects fronto-striatal dysfunction (Dirnberger and Jahanshahi, 2013), and has been shown 
to be partly reversible by dopaminergic medication (Kehagia et al., 2013). In contrast, the second 
cluster of PD patients has been described to show early deficits in non-frontal cognitive functions 
(such as visuospatial abilities) that are predictive of rapid progression to dementia (PDD) 
(Robbins and Cools, 2014; Williams-Gray et al., 2009). PDD involves a wide range of cognitive 
and psychiatric symptoms that have been attributed to dysfunction in temporal and parietal areas 
of the cortex (Gratwicke et al., 2015; Kehagia et al., 2013). These cognitive symptoms in PDD 
(assessed, for instance, using the Mini-Mental State Examination, MMSE, Folstein et al., 1975) 
are apparently unresponsive to dopamine substitution, but may instead benefit from cholinergic 
treatment (Emre et al., 2004; Robbins and Cools, 2014). 
Apart from the discussion of dopaminergic/cholinergic medication for dementia in PD, it 
is important to note that the effect of dopaminergic medication on cognition is variable – even in 
early (non-demented) PD patients. While in these patients dopaminergic medication can improve 
cognitive functions mediated by the motor or associative fronto-striatal circuits, it can lead to 
‘overdosing’ and impairment of performance on cognitive tasks that rely on the limbic or 
orbitofrontal circuits, which are not dopamine-depleted in early stages of the disease (Cools et al., 
2001; Cools, 2006; Gotham et al., 1988; Jahanshahi et al., 2010; Swainson et al., 2006). This 
issue will be discussed in more detail in Section 4.4. 
1.2 Cognitive ERPs 
In the next two paragraphs, we will introduce classical ERPs that might qualify as 
indicators of cognitive decline in PDD, as well as ERP correlates of executive processes that have 
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been used to examine the specific cognitive sequelae of fronto-striatal dysfunction in non-
demented PD patients. 
1.2.1 Classical cognitive ERPs 
The P3b, first described by Sutton et al. (1965) and often also referred to as P300, is 
perhaps the most-studied ERP component, partly due to its relatively large amplitude and facile 
elicitation in experimental contexts (for reviews, see Kok, 2001; Polich, 2007). It emerges as a 
positivity with a parietal scalp distribution and is possibly related to noradrenergic signaling from 
the locus coeruleus (Nieuwenhuis et al., 2005). Timing of this ERP may range widely, from 250 
ms and extending to up to 1000 ms. The P3b is commonly assessed using the ‘oddball’ paradigm, 
in which a random sequence of stimuli (of either visual, auditory or somatosensory modality) is 
presented (Fig. 1). Participants are required to mentally count or to press a button in response to 
rare target events (‘oddballs’) and hence to discriminate them from frequent standard events. In 
this two-stimulus oddball paradigm, stimuli belonging to the target category elicit the P3b, and 
P3b amplitudes increase with decreasing target category probability (Kolossa et al., 2013; Ritter 
and Vaughan, 1969). This inverse relation between the probability of the target category and P3b 
amplitude implies that P3b is elicited only after the stimulus has been evaluated as belonging to 
the frequent or infrequent category. Hence, P3b peak latency is commonly assumed to co-vary 
with the duration of stimulus evaluation. This relationship between P3b latency and stimulus 
evaluation time is further supported by the observation that P3b latency increases when the 
categorization of a stimulus as belonging to the target or standard category becomes more 
difficult (Kutas et al., 1977; Luck, 2014). In contrast, P3b latency appears to be relatively 
insensitive to increased demands for response selection (McCarthy and Donchin, 1981). Given 
the link between P3b peak latency and the duration of stimulus evaluation, P3b recordings can be 
used to decompose the variance in the speed of behavioral responses into an early portion 
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associated with stimulus evaluation and a late portion associated with post-perceptual processing. 
In addition, the amplitude of the P3b has been proposed to reflect the amount of attentional 
resources allocated to the target stimulus (Johnson, 1988). 
If task-irrelevant novel and/or salient stimuli are added to the oddball task (i.e., three-
stimulus oddball; Fig. 1), these deviant events also elicit a positive-going ERP waveform that has 
been labeled P3a (usually elicited by salient deviants; Squires et al., 1975) or novelty P3 (usually 
elicited by novel deviants; Friedman et al., 2001). As P3a and novelty P3 are commonly regarded 
as variants of the same ERP waveform (Polich, 2007; Spencer et al., 2001), we will collectively 
refer to both waveforms as P3a in the remainder of this review. The P3a can be distinguished 
from the P3b on the basis of earlier peak latency and a scalp distribution with a fronto-central 
maximum, relative to the more parietally distributed P3b maximum (Polich, 2007). The relation 
between P3a and P3b has not been fully clarified and remains an issue of theoretical debate. The 
P3a is often portrayed in the context of distraction through task-irrelevant events (Escera and 
Corral, 2007); however, the processing of salience and/or novelty may constitute an important 
alerting (or orienting) response of the brain to surprising events (Barceló et al., 2002; Kopp and 
Lange, 2013; Lange et al., 2015; Seer et al., 2016). EEG source modeling of scalp-recorded 
ERPs, intracranial investigation, studies with patients with focal brain lesions, and combined 
ERP/functional neuroimaging (fMRI) studies converge in suggesting that the main regions 
consistently attributed to generating the scalp-recorded P3b include the temporal-parietal junction 
and the medial temporal lobes, whereas generation of the P3a has been attributed to the prefrontal 
cortex (Polich, 2007; Volpe et al., 2007; Wronka et al., 2012). 
The MMN (Näätänen et al., 1978; for reviews, see Näätänen and Winkler, 1999; 
Näätänen et al., 2007) is elicited by changes in auditory stimulation, and MMN amplitudes are 
related to the discriminability of these changes. The MMN is typically seen as a fronto-central 
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negativity, occurring in the latency range around 100–250 ms. It is generated from the auditory 
cortices bilaterally, but there may also be a contribution from the right lateral prefrontal cortex 
(Giard et al., 1990). The MMN is thought to reflect an automatic process that detects differences 
between an incoming stimulus and the sensory memory trace of immediately preceding stimuli 
(Näätänen et al., 2007). 
1.2.2 Cognitive ERP correlates of executive control 
One of the standard tasks to examine inhibitory control is the Go/NoGo task, in which 
participants are asked to respond to some stimuli and to refrain from responding to other stimuli 
(Fig. 1). ERPs measured in Go/NoGo tasks consist of a negative deflection (NoGo-N2) and a 
subsequent positivity (NoGo-P3) in NoGo-trials as compared to Go-trials (Falkenstein et al., 
1995; Karlin et al., 1970). Both ERP waveforms show fronto-central scalp topography. 
The NoGo-P3 has been related to neural processes for inhibition by many researchers 
(e.g., Roberts et al., 1994). However, the NoGo-P3 could simply reflect a separate inhibition-
monitoring process (Bruin et al., 2001; Huster et al., 2013; Roche et al., 2005). Accordingly, the 
NoGo-P3 has been associated with the efficiency of inhibitory control and with the evaluation of 
the inhibition process (Liotti et al., 2005; Schmajuk et al., 2006; see also Kopp et al., 1996a). The 
network underlying NoGo-P3 generation shows a broad distribution of sources including medial 
prefrontal and pre-central sources and associations with pre-supplementary motor area (SMA), 
temporo-parietal regions, the insulae as well as parts of the basal ganglia (Huster et al., 2013). 
The NoGo-N2 amplitude is smaller and NoGo-N2 latency is delayed in participants with 
higher error (false alarm) rates compared to participants with lower error rates (Falkenstein et al., 
1999), supporting the view that the NoGo-N2 is related to inhibitory processing (Kopp et al., 
1996a). The view that the NoGo-N2 reflects cognitive processes for inhibition was challenged by 
Nieuwenhuis et al. (2003) and Donkers and van Boxtel (2004), who suggested that the NoGo-N2 
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reflects response conflict rather than inhibitory control. This ‘response conflict’ view is consistent 
with the fact that simultaneous activation of competing response tendencies – as it occurs in 
conflict (or interference) tasks (such as the Eriksen flanker task, Eriksen and Eriksen, 1974; see 
Fig. 1) – is associated with enhanced fronto-central (conflict-)N2 amplitudes. Thus, both the 
NoGo-N2 (Kopp et al., 1996a) and the conflict-N2 elicited in interference tasks (Kopp et al., 
1996b) have been claimed to indicate the resolution of response conflict by executive control 
processes (Folstein and Van Petten, 2008). EEG source modeling (Bekker et al., 2005; Bokura et 
al., 2001) and combined ERP/fMRI (Mathalon et al., 2003) studies suggest that the NoGo-N2 and 
conflict-N2 reflect activity in medial and lateral prefrontal cortices. The medial source seems to 
be located in the mid-cingulate cortex (Huster et al., 2013), whereas the lateral source has been 
attributed to the right (Lavric et al., 2004) and the left inferior prefrontal cortex (Huster et al., 
2010). Note that the available data are still insufficient to unambiguously relate NoGo-N2, 
conflict-N2, and NoGo-P3 ERP measures to specific executive functions (Huster et al., 2013). 
Incorrect responses in various choice-response tasks are typically followed by a fronto-
centrally distributed negative deflection that has been termed ‘error negativity’ (Ne; Falkenstein 
et al., 1991) or ‘error-related negativity’ (ERN; Gehring et al., 1993). It starts around the time of 
an overt erroneous response and peaks around 50–100 ms later. The Ne/ERN has thus been 
regarded as a correlate of performance monitoring, and several models have sought to explain its 
functional significance (Bernstein et al., 1995; Botvinick et al., 2001; Holroyd and Coles, 2002; 
for review and discussion, see Ullsperger et al., 2014b). Specifically, the reinforcement learning 
model of the Ne/ERN (Holroyd and Coles, 2002) views the Ne/ERN as neural activity related to 
the processing of a prediction error which is conveyed by midbrain dopamine neurons and 
broadcasted to prefrontal cortices. Accordingly, the Ne/ERN is considered to be generated in the 
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posterior medial prefrontal cortex (mainly the anterior mid-cingulate cortex; Ullsperger et al., 
2014a). 
1.3 The present review 
In the following, we comprehensively review the literature on the ERP correlates of 
cognitive dysfunction in PD. Our review is based on an exhaustive literature search using ISI 
Web of Science, PubMed, and Google Scholar, conducted in late 2014/early 2015 and updated in 
early 2016. To be included in this review, studies were required to report at least one ERP 
measure recorded from at least two patients with PD (i.e., single-case studies were not 
considered). Studies focusing on movement-related potentials in PD are reviewed by us in a 
related article (Georgiev et al., 2016). A small number of studies were published after we had 
updated our literature review (i.e., during the review and revision process), and these studies 
(Garrido-Vásquez et al., 2016; Kaufman et al., 2016; Tang et al., 2016) were not included in the 
systematic overviews presented below. From the review, it becomes evident that two major lines 
of cognitive ERP research in PD have been pursued over the last three decades. On the one hand, 
clinically-oriented research has focused on recording classical ERPs elicited in simple 
discrimination tasks. Specifically, there is a long-standing debate as to whether P3b latency might 
qualify as an electrophysiological biomarker for PD. Here, we provide a quantitative overview of 
P3b studies in PD which reveals that the prolongation of the P3b latency is related to the presence 
of dementia in PD rather than to PD itself. On the other hand, theory-driven research has 
investigated a broader variety of ERPs as candidate biomarkers of cognitive dysfunction in PD. 
These studies used diverse tasks to identify the neural substrates of PD-specific cognitive 
alterations, most notably though not exclusively, in the domain of executive functioning. ERP 
research in this area has revealed particularly intriguing insights with regard to attentional 
orienting (P3a), conflict processing (N2), and performance monitoring (Ne/ERN) in PD. In sum, 
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based on the evidence reviewed, we will establish that the clinically-oriented research on 
classical cognitive ERPs and the experimentally-oriented analyses of ‘executive ERPs’ 
complement each other in revealing the multifaceted nature of the neural substrates of cognitive 
deficits in PD (see above). 
2 P3b: allocation of attentional resources and stimulus evaluation duration 
The cognitive ERP most frequently studied in patients suffering from PD is the P3b. The 
P3b peak latency has been considered a promising tool to quantify cognitive impairments 
(particularly cognitive slowing) associated with PD (Hansch et al., 1982). The P3b latency can be 
quantified in the absence of any overt response (e.g., by instructing the participant to silently 
count the target stimuli). Hence, in contrast to response time measures, P3b latency may be a 
good measure for the efficiency of cognitive processing in PD which is not confounded by the 
patients’ motor impairments and can be measured even in patients with severe symptoms. 
Building on this premise, dozens of research groups have recorded the oddball P3b in PD patients 
to examine whether patients differ from healthy controls with regard to the speed of stimulus 
evaluation, as indicated by P3b latency, or with regard to the allocation of attention, as indicated 
by P3b amplitude. Further issues related to P3b measures are whether they can help to 
discriminate PD patients with and without dementia, and whether P3b assessment can contribute 
to the differential diagnosis of idiopathic PD from other types of parkinsonism. How far have we 
come with regard to answering these questions? 
We have identified 65 studies that present P3b data from 74 samples of PD patients 
(Table 1). All of these studies applied the oddball paradigm and compared at least one P3b 
measure (latency or amplitude) between the patient group and an age-matched group of healthy 
controls. In 54 studies that quantified and compared P3b amplitudes, PD patients’ amplitude 
measures were decreased in ten (19%), increased in five (9%), and indistinguishable from 
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waveforms recorded in healthy controls in 39 (72%) samples, a pattern that might be best 
explained by chance variation. 
P3b latency on the other hand was significantly prolonged in 39 (or 53%) of the samples, 
with only one study reporting shorter P3b latencies in PD patients than in controls. While such a 
large proportion of significant results can certainly not be attributed to error variance, it also 
highlights that there is no reliable pattern of P3b prolongation in PD. Basically, two alternative 
explanations might account for this observation: either the magnitude of the group difference 
between PD patients and healthy controls is not large enough, or the group difference is 
substantially influenced by a moderating factor. If the former is the case, studies involving a large 
sample size should be more likely to detect significant P3b latency differences. However, large-
sample studies (as defined by a median split over N; the median number of participants was N = 
38) did not generate a significantly larger number of significant results than small-sample studies 
(large N: 58%, small N: 49%; χ2(1, n = 73) = 0.69, p = 0.41). To address the second possibility, 
we tested whether the likelihood of finding significantly prolonged P3b latencies in PD patients 
depends on a number of sample characteristics (medication status [on vs. off dopamine 
replacement therapy vs. non-selected samples], age, disease duration, Hoehn & Yahr stage [HY], 
dementia status [diagnosis of dementia vs. no diagnosis of dementia vs. non-selected samples]), 
or on task settings of the oddball paradigm (two-stimulus vs. three-stimulus oddball, modality, 
target probability, response mode). For this purpose, continuous measures were transformed into 
binary variables by median split (median HY: 2.33; median age: 64.1 years; median disease 
duration: 5.4 years; median target probability: 0.20). As displayed in Fig. 2, the likelihood of 
finding significant P3b prolongations in PD was not affected by any of the factors (all χ2 < 2.46, 
all p > 0.11) with the exception of the presence or absence of a diagnosis of dementia in the PD 
sample (χ2(1, n = 72) = 11.74, p = 0.001) and HY stage (χ2(1, n = 54) = 4.75, p = 0.03). When 
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included in a logistic regression model (R2 = 0.27), only dementia status (Exp(B) = 6.63, 95% CI 
= [1.54– 28.44], Wald(1) = 6.47, p = 0.01), but not HY (Exp(B) = 2.31, 95% CI = [0.68–7.84], 
Wald(1) = 1.79, p = 0.18) emerged as a significant predictor of the prolongation of P3b latency. 
When demented PD patients were excluded from consideration, only 19 of 50 studies (38%) 
yielded significant P3b latency differences. However, 10 out of 14 studies on non-selected 
samples and all of the eight studies on samples that only included demented PD patients 
demonstrated significantly increased P3b latencies in these patients in comparison to healthy 
controls. 
While P3b latency appears to be a sensitive biomarker for PD dementia (PDD), the data 
accumulated and reviewed here do not support previously suggested hypotheses with regard to 
the moderating factors of the prolongation of P3b latency in PD. For instance, Hayashi et al. 
(1996) proposed that P3b latency prolongation depends on disease severity, and Kutukcu et al. 
(1998) suggested that P3b in non-demented PD patients is only prolonged when overt responses 
are required. However, even when we excluded samples involving demented patients from the 
analysis, the likelihood of significant P3b prolongation was neither affected by HY stage (χ2(1, n 
= 37) = 0.59, p = 0.44), nor by response mode (χ2(1, n = 46) = 1.31, p = 0.25; in fact, studies were 
numerically more likely to yield significant group differences when they did not require 
participants to make an overt response). In sum, there is reliable evidence for prolongation of P3b 
latency in demented, but not in non-demented PD patients, suggesting that a decrease in the speed 
of stimulus evaluation occurs in PDD, but not in PD. 
2.1 P3b and the specificity of cognitive changes in PD 
Having established that P3b latency is sensitive to dementia in PD, it should not be 
surprising to find associations between P3b latency and global measures of cognitive ability in 
PD patients. The degree of global cognitive impairment has been linked to P3b latency by studies 
 
 
14 
 
showing correlations between P3b latency and neuropsychological measures of general 
intelligence (Bodis-Wollner et al., 1995; Hansch et al., 1982; Katsarou et al., 2004), processing 
speed (O'Donnell et al., 1987), and, most frequently, the global score on the MMSE (Lukhanina 
et al., 2009; Maeshima et al., 2002; Matsui et al., 2007; Sartucci et al., 1990; Stamenović et al., 
2005; Tachibana et al., 1997; but see Elwan et al., 1996; Lukhanina et al., 2008). 
Some studies have also evaluated the relationship between P3b latency and cognitive 
functions that might be indicative of specific fronto-striatal alterations. Specifically, P3b latency 
appears to be related to prototypical executive functions such as set-shifting (Iijima et al., 2000; 
Katsarou et al., 2004; Stamenović et al., 2005; but see Stanzione et al., 1998), trail-making 
(Matsui et al., 2007; Stamenović et al., 2005; but see Elwan et al., 1996), verbal fluency (Bodis-
Wollner et al., 1995; Chen et al., 2006), working memory (O'Donnell et al., 1987), and planning 
(Kim et al., 1995), even in non-demented patients. However, to date it is not clear whether the 
association between P3b latency and executive functioning in PD is actually specific, because 
previous studies did not control for the variance shared with measures of global cognitive ability. 
Future studies involving larger samples sizes and neuropsychological test batteries are required to 
establish whether P3b latency relates to distinct or generalized alterations in cognitive 
functioning in PD. 
Along similar lines, more data are needed to support the notion that P3b latency 
prolongation can serve as a diagnostic tool to differentiate PD or PDD from other types of 
dementia or parkinsonian syndromes. P3b latency has been found to be prolonged in multiple 
system atrophy (MSA; Deguchi et al., 2001; Kamitani et al., 2002; Kamitani and Kuroiwa, 2009), 
corticobasal degeneration (CBD; Takeda et al., 1998; Wang et al., 2000), progressive 
supranuclear palsy (PSP; Pierrot-Deseilligny et al., 1989; Takeda et al., 1998), dementia with 
Lewy bodies (DLB; Kurita et al., 2010), and Alzheimer’s disease (AD; Golob and Starr, 2000; 
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Olichney et al., 2011; Polich et al., 1990). Only a few studies have recorded the P3b in more than 
a single group of patients to allow for direct comparison of P3b latency across diagnostic groups. 
In general, P3b latency prolongation, while being related to the progression of cognitive decline 
in different types of dementia (Polich et al., 1986), does not seem to differ between AD and PDD 
patients (Filipović et al., 1990; Hanafusa et al., 1991; Tachibana et al., 1992; but see Goodin and 
Aminoff, 1986). However, more recent work by Kurita et al. (2010) suggests that P3b latency 
prolongation might in fact be more pronounced in PDD than in AD, especially in those PDD 
patients who suffer from visual hallucinations. 
A further promising study involving non-demented patients suffering from different 
parkinsonian syndromes demonstrated that P3b latency was only prolonged in CBD, but not in 
non-demented PD or PSP patients, while P3b amplitude was selectively decreased in PSP 
patients (Wang et al., 2000). Whereas the dissociation regarding P3b latencies was not replicated 
in a study with a similar design (Pirtošek et al., 2001), P3b amplitude appears to be reproducibly 
larger in non-demented PD patients when compared to patients suffering from PSP (Johnson, 
1995; Pirtošek et al., 2001). Clearly, however, more comparative studies involving  sufficient 
sample sizes are required to establish the utility of P3b amplitude measures in differentiating PD 
and PSP. Most other approaches to use P3b measures for differential diagnosis were rather 
exploratory and were not followed up by systematic replication. In the study by Antal et al. 
(2000), P3b latency was substantially prolonged in PD patients, but not in patients suffering from 
essential tremor (ET). More recent work by Balaban et al. (2012) demonstrated, however, that ET 
patients also showed marked prolongations of P3b latency. Moreover, P3b latency appeared to be 
shorter in juvenile PD when compared to idiopathic PD patients (Kaseda et al., 1996), while the 
extent of P3b latency prolongation was observed to be similar in idiopathic PD and vascular PD 
patients (Oishi et al., 1996). However, in the study by Oishi et al. (1996), P3b latency was 
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reduced by levodopa administration in idiopathic PD, but not in vascular PD. This latter finding 
illustrates a further potential field of application for P3b measures: the study of medication 
effects on cognitive functioning in PD. 
2.2 P3b and dopaminergic medication in PD 
Investigations comparing P3b measures in PD patients on and off medication have been 
used (a) to improve the understanding of dopaminergic involvement in PD-related cognitive 
deficits (Růžička et al., 1994) and (b) as a human model to study dopaminergic contributions to 
P3b generation (Stanzione et al., 1991). In most of the studies on levodopa effects, never-
medicated PD patients or patients who underwent a drug washout period (12 h – 14 days) were 
tested on an oddball procedure, first off and then on medication. We identified nine studies 
employing such a study design with five of them demonstrating a reduction of P3b latency 
following levodopa administration (Lukhanina et al., 2009; Oishi et al., 1996; Sohn et al., 1998; 
Stanzione et al., 1991; Starkstein et al., 1989). However, P3b latency was not significantly 
decreased by levodopa in the studies by Chia et al. (1995), Kobayashi et al. (2004), and Mathis et 
al. (2014) and even increased under levodopa in the study by Prasher and Findley (1991). 
Although the majority of these studies suggest that PD-related P3b latency prolongation is 
normalized by levodopa, this finding is far from reliably established. First, none of the studies 
employed a placebo-controlled design or an on vs off medication counterbalancing procedure 
controlling for order effects. Hence, medication effects were always confounded with potential 
effects of learning, fatigue or habituation. In a recent study that controlled for these factors 
(Georgiev et al., 2015), no differences in P3b latency have been found as a function of PD 
patients’ dopaminergic status (see also Vieregge et al., 1994). Second, it has to be noted that 
sample sizes were considerably smaller in the studies reporting a levodopa-associated decrease in 
P3b latency (mean N = 14.8) than in the studies reporting no such effect (mean N = 23.5; pone-tailed 
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t-test = 0.03), thus challenging the reliability of the proposed levodopa effect. With regard to P3b 
amplitude, no differences associated with levodopa treatment in PD have been reported to date. 
Only a few studies are available on the effects of dopamine agonists on P3b latency in 
PD. While neither amplitude nor latency of the P3b was altered by bromocriptine administration 
(Rumbach et al., 1993), apomorphine appeared to increase P3b latency and to decrease P3b 
amplitude (Růžička et al., 1994, 1998). Notably, ERP measures were negatively affected in the 
latter studies while substantial motor improvements were observed following drug 
administration, indicating that P3b might potentially qualify as an objective indicator of the 
cognitive side effects of dopamine agonists. Moreover, in a more controlled, experimental design 
P3b latency was surprisingly found to be prolonged in PD patients under the influence of the 
peptide hormone cholecystokinin, which is thought to increase dopaminergic firing in the basal 
ganglia (Smolnik et al., 2002). 
Medication studies targeting non-dopaminergic mechanisms identified shortened P3b 
latencies following administration of the glutamate antagonist amantadine (Bandini et al., 2002), 
while P3b measures appeared not to be affected by the noradrenergic agonist naphtoxazine 
(Bédard et al., 1998). More recent studies have also focused on the effect of deep brain 
stimulation (DBS) of the subthalamic nucleus (STN) on scalp-recorded P3b amplitudes of PD 
patients (Gerschlager et al., 2001; Kovacs et al., 2008; Naskar et al., 2010). P3b latency and 
amplitude have been found to be unaffected by STN DBS in all of these studies. 
In summary, the lack of consistent effects of both dopaminergic medication and STN 
DBS on P3b measures in PD suggests that the cognitive mechanisms reflected by the P3b might 
not depend to a crucial extent on the integrity of dopaminergic pathways. Specifically, PD-related 
P3b latency prolongation cannot easily be attributed to nigro-striatal dopamine depletion, a 
conclusion that is further supported by the evidence reviewed above that P3b latency alterations 
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are predominantly observed in PDD patients for whom signs of neurodegeneration involve wide 
areas of the neocortex (Wolters and Braak, 2006). 
2.3 P3b in PD: conclusions and future directions 
Over the last decades, the study of cognitive ERPs in PD was largely dominated by an 
interest in potential P3b alterations and their functional significance. The evidence from a large 
number of independent investigations can be summarized as the prolongation of P3b latency 
being sensitive to the presence of dementia in PD, whereas P3b latency is not generally 
prolonged in non-demented PD patients (Fig. 3, left panel). P3b latency prolongation cannot 
easily be reversed by means of dopamine replacement therapy or DBS, and it is not specifically 
related to executive function deficits, which are characteristic of fronto-striatal dysfunction in 
PD. Congruent with the prevailing interpretation of P3b latency as a measure of stimulus 
evaluation time, P3b latency prolongation might rather serve as a sensitive biomarker for global 
cognitive decline as it occurs in PDD. However, P3b latency prolongation is not a specific feature 
of PDD, as it can also be observed in other dementing diseases, including Alzheimer’s disease, 
and atypical parkinsonian syndromes. 
Future investigations of P3b latency prolongation in PD should explore the moderators of 
this effect, i.e., clarify under which conditions P3b latency is prolonged in PD. Studies addressing 
this question might benefit from manipulating the demands for stimulus evaluation. For instance, 
stimulus evaluation time (as mirrored in P3b latency) is typically shorter when target stimuli 
occur in a predictable manner; however, this shortening of latency by predictability does not 
occur in PD patients (Fogelson et al., 2011). Similarly, PD-related P3b latency prolongation has 
been shown to depend on the choice of the task-relevant stimulus dimension (with prolonged 
motion discrimination time and normal color discrimination time in PD patients) and thus on the 
recruited processing pathways within the visual system (Arakawa et al., 1999). 
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In contrast to its latency, P3b amplitude has generally been found to be unaltered in PD 
patients, even in those suffering from dementia. While indicating that PD patients do not seem to 
have difficulties allocating processing resources to relevant target stimuli in the oddball 
paradigm, this finding is not particularly surprising. The detection of clearly identifiable target 
stimuli in the absence of any conflicting information is certainly not the ideal task to tax those 
cognitive processes that may be impaired in PD or in PDD. In the future, P3b investigations that 
are tailored to PD-related cognitive deficits may be more promising. 
A recent example of such a study has been reported by Verleger et al. (2013) who 
measured the P3b in a flanker paradigm (Fig. 1) not only in the conventional way (i.e., stimulus-
synchronized), but also time-locked to the participants’ responses. In healthy controls, stimulus- 
and response-locked P3b amplitudes were indistinguishable, suggesting that the associated 
stimulus-response links (possibly supported by the basal ganglia) were largely intact. However, 
in PD patients, response-locked amplitudes were substantially smaller than stimulus-locked 
potentials, and the authors attributed the response-locked P3b amplitude attenuation in PD 
patients to nigro-striatal dopamine depletion. 
In a further study (Münte et al., 2015), P3b has been recorded in a dual-task paradigm to 
test the hypothesis that PD may be associated with decreased attentional processing capacity. PD 
patients and healthy controls were presented with a classical two-stimulus oddball procedure as a 
secondary task while they also completed a primary task that placed either high (random number 
generation; participants were asked to press number keys in a random order) or low (ordered 
number generation; participants are asked to press number keys in a canonical order) demands on 
participants’ processing capacities. In healthy controls rare target stimuli in the oddball task 
elicited P3b waveforms of similar amplitude in the high-demanding and in the low-demanding 
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task. In PD patients, however, P3b amplitude was selectively decreased in the more demanding 
version of the primary task, indicating a PD-related limitation of attentional processing resources. 
The data that were obtained from these two studies illustrate that P3b amplitudes might 
indeed provide interesting insights about neural and cognitive dysfunctions associated with PD. 
One prerequisite for successful P3b-based ERP studies of PD is to tailor experimental designs 
and data analyses toward specific hypotheses about PD-related neural and cognitive alterations. 
3 P3a, mismatch negativity, and reorienting negativity: novelty processing and 
deviance detection 
PD patients may have difficulties shifting attention and adapting to novelty in the 
environment (Dubois and Pillon, 1997; Rustamov et al., 2014). Hence, investigating ERP 
responses related to attentional processes in PD patients may be of particular relevance for 
understanding some of the cognitive changes associated with the disease. In this context, previous 
research has focused on the assessment of the P3a waveform in the three-stimulus oddball task 
(Fig. 1) as well as in the distraction paradigm (see below). 
Specifically, P3a measures have been analyzed in about a dozen studies involving patients 
with PD (Table 2). The emerging findings are rather heterogeneous. While only two studies 
reported prolonged P3a latencies in PD, it is remarkable that neither of these studies reported PD-
related P3b prolongation in response to target oddball stimuli (Tsuchiya et al., 2000; Zeng et al., 
2002), suggesting a potential dissociation between P3a and P3b latency in PD. This dissociation 
is further supported by the observation that P3a latency does not seem to differ between PDD 
patients and PD patients without dementia (Tachibana et al., 1992; Toda et al., 1993). 
P3a amplitude has been found to be attenuated in PD in some studies (Li et al., 2005; 
Solís-Vivanco et al., 2011, 2015; Tsuchiya et al., 2000; Wang et al., 1999, 2000), but not in 
others (Bocquillon et al., 2012; Gaudreault et al., 2013; Georgiev et al., 2015; Hozumi et al., 
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2000; Pirtošek et al., 2001; Tachibana et al., 1992; Toda et al., 1993; Zeng et al., 2002). These 
differences can hardly be explained by different task characteristics, as, for instance, the studies 
by Tachibana et al. and Toda et al. (no amplitude reduction) used the same procedures as the 
studies by Li et al. and Wang et al. (significant amplitude reduction). It seems more likely that the 
PD-related P3a amplitude attenuation constitutes a medium-sized effect that sometimes fails to 
reach significance due to insufficient statistical power (Cohen, 1992). Enhanced P3a amplitudes 
in oddball tasks have been interpreted to indicate stronger distractibility in several clinical 
populations (Escera et al., 2000). In addition, smaller P3a amplitudes obtained from three-
stimulus oddball tasks have been associated with more efficient performance in more demanding 
tasks (Lange et al., 2015). Against this background, PD-related attenuation of P3a amplitudes in 
three-stimulus oddball tasks may indicate enhanced resistance to distraction in PD patients. 
Alternatively, reduced P3a amplitudes may reflect a PD-related impairment in directing attention 
to potentially important changes in the environment (Barry et al., 2011). 
The functional significance of orienting responses to novel stimuli is illustrated by a study 
by Schomaker et al. (2014). In this study, patients and controls were required to memorize words 
that were either presented in a standard font or in one of multiple novel fonts. Healthy controls 
showed the typical von Restorff effect (i.e., better memory for words that were written in novel 
fonts; von Restorff, 1933). In contrast, PD patients did not benefit from the word being written in 
a novel font. Likewise, P3a amplitudes were enhanced in response to novel font words in 
controls, but not in PD patients, suggesting that patients have difficulties allocating attentional 
resources to novel features (Schomaker et al., 2014). 
The adaptive nature of attentional orienting is further illustrated by the sensitivity of P3a 
amplitude to habituation. As a cortical correlate of the orienting response, the P3a amplitude 
decreases with an increasing number of stimulus repetitions (Friedman et al., 2001). This 
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habituation is entirely lacking in PD patients (Tsuchiya et al., 2000), thereby mirroring the pattern 
observed in patients with dorsolateral prefrontal cortex lesions (Knight, 1984). In this context, it 
is remarkable that the PD-related P3-amplitude attenuation has been related to perseverative 
behavior on the Wisconsin Card Sorting Test (WCST; Heaton et al., 1993), a well-established 
neuropsychological test of cognitive flexibility (Tsuchiya et al., 2000). Perseverative tendencies 
on this test are commonly regarded as a hallmark of executive dysfunctions in both PD patients 
(Dirnberger and Jahanshahi, 2013; Gotham et al., 1988) and patients with prefrontal cortex 
lesions (Demakis, 2003; Milner, 1963). In conclusion, P3a amplitude attenuation in PD patients 
may be an electrophysiological correlate of PD-related behavioral deficits in adjusting rapidly 
and efficiently to novel environmental demands, an executive function that is supported by the 
integrity of fronto-striatal loops (Monchi et al., 2001, 2004). 
Another recent finding that underscores the functional relevance of P3a in PD has been 
reported by Solís-Vivanco et al. (2015). These authors found the degree of P3a amplitude 
attenuation in 55 PD patients to be linearly related to disease duration, even when controlling for 
covariates such as age and MMSE score. This finding has been suggested to indicate that P3a 
amplitude may qualify as a reliable biomarker of disease progression (Solís-Vivanco et al., 2015). 
Along similar lines, the P3a amplitude attenuation has been found to be associated with apathy 
(Mathis et al., 2014) and akinesia (Wang et al., 2000) in PD patients. Further studies investigating 
P3a amplitude attenuation in PD and the links between this ERP measure and clinical or 
cognitive variables are essential for establishing the utility of P3a measurement for an 
understanding of neural and cognitive sequelae of PD. 
However, the utility of P3a amplitude measures for differential diagnosis seems limited. 
In the study by Wang et al. (2000), the P3a was reduced in PD, but not in CBD, while the 
opposite pattern was observed by Pirtošek et al. (2001). Interestingly, however, P3a latency, but 
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not P3a amplitude or P3b measures, significantly differed between PDD patients and AD patients 
(Tachibana et al., 1992). 
When the P3a is recorded in the distraction paradigm (Schröger and Wolff, 1998), as for 
example in the studies by Solís-Vivanco et al. (2011, 2015), it is typically preceded by the 
Mismatch Negativity (MMN), an index of relatively automatic deviance detection (Näätänen et 
al., 2007). In the distraction paradigm, participants are instructed to attend to one stimulus 
dimension (e.g., tone duration), while the presented stimuli also vary on a second, task-irrelevant 
dimension (e.g., tone pitch). Unexpected changes in the task-irrelevant stimulus dimension (e.g., 
a rare high-pitched tone in a series of frequent low-pitched tones) elicit the MMN. Alternatively, 
the MMN can also be recorded in response to oddball stimuli when participants are asked to 
ignore the oddball sequence (e.g., Karayanidis et al., 1995; Pekkonen et al., 1995). Further, in the 
distraction paradigm, MMN and P3a are followed by the Reorienting Negativity (RON) that is 
related to reorienting attention toward performing the task following distraction (Schröger and 
Wolff, 1998). 
Overall, studies of MMN in PD do not point to a pronounced disease-related deficit in 
pre-attentional mechanisms of deviance detection (Table 2). Although MMN amplitude in 
response to deviant sounds has been reported to be attenuated in non-demented PD patients in 
one study (Pekkonen et al., 1995), no such differences could be found in six other studies 
(Brønnick et al., 2010; Karayanidis et al., 1995; Pekkonen et al., 2000; Solís-Vivanco et al., 2011, 
2015; Vieregge et al., 1994). However, in the study by Brønnick et al. (2010), MMN amplitude 
was markedly attenuated in PDD patients and, surprisingly, the extent of the MMN attenuation 
was more pronounced in PDD patients than it was in AD or DLB patients. Hence, MMN 
amplitude reduction might share the sensitivity of P3b latency prolongation for PDD (see above) 
without suffering from a lack of specificity. 
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With regard to RON, only limited data have been reported so far. No differences in the 
RON amplitude have been observed when PD patients were on dopaminergic medication (Solís-
Vivanco et al., 2011; Solís-Vivanco et al., 2015). However, the RON amplitude was significantly 
reduced in non-medicated patients when compared to both medicated patients and healthy 
controls (Solís-Vivanco et al., 2011). Hence, the RON amplitude might be susceptible to 
dopaminergic influence. Future studies employing the distraction paradigm in PD patients 
varying in presence/absence of dementia and medication status are needed to further investigate 
the differential sensitivity of MMN and RON to the presence of PDD and to variations in 
dopamine activity, respectively. 
3.1 P3a, MMN, and RON in PD: conclusions and future directions 
In contrast to the good evidence for P3b latency prolongation in PDD, the available MMN 
data are much less clear-cut, but they suggest that MMN amplitude may be attenuated in PDD in 
a nosologically specific manner. The RON obtained from distraction paradigms potentially 
provides a state marker of nigro-striatal dopamine depletion in PD (Solís-Vivanco et al., 2011). 
Overall, the P3a amplitude findings in PD must be considered equivocal, and it appears that 
differences between PD patients and controls are not very large. Researchers interested in 
studying this waveform in PD should focus on systematically deducted research questions, and 
tailor their paradigms to precisely answer these questions. Studies should be conducted in large 
samples to obtain a reliable estimate of the effect sizes. One study (Solís-Vivanco et al., 2015) 
reported an association between P3a amplitude attenuation and disease duration in PD. Future 
studies employing longitudinal designs are required to examine the utility of P3a amplitude as a 
biomarker of disease progression in PD. 
4 NoGo-P3, N2, and error(-related) negativity: executive control 
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The Go/NoGo task (Fig. 1) is among the standard tasks to examine executive control in 
PD. ERPs measured in Go/NoGo tasks consist of more pronounced stimulus-synchronized 
negative deflections (NoGo-N2) and a subsequent positivity (NoGo-P3) in NoGo-trials as 
compared to Go-trials with a fronto-central scalp topography. Fronto-centrally distributed 
stimulus-synchronized (conflict-)N2 waveforms are also observed in conflict (or interference) 
tasks (such as the Eriksen flanker task, see Fig. 1). Thus, both the NoGo-N2 and the N2 elicited 
in interference tasks have been claimed to indicate the resolution of response conflict by 
executive control processes (Kopp et al., 1996a,b). Incorrect responses in various choice-response 
tasks are typically followed by a prominent Ne/ERN, i.e., a fronto-centrally distributed, response-
synchronized negative deflection in ERP waveforms. The Ne/ERN provides a neurophysiological 
indicator of the integrity of neural networks for performance monitoring (Ullsperger et al., 
2014a). 
4.1 NoGo ERPs: response conflict and inhibition 
As will be seen, the studies assessing ERPs in Go/NoGo tasks (Pires et al., 2014; see Fig. 
1) in PD differ considerably with regard to the statistical comparisons which they report (Table 
3). Some studies report group main effects on ERP amplitudes and latencies (i.e., disregarding 
potential differences between Go-ERPs and NoGo-ERPs), whereas other studies report trial-
specific effects (e.g., Go-P3, NoGo-P3). Furthermore, some studies refer to the difference 
potential that is obtained by subtracting Go-ERP amplitudes or latencies from the respective 
NoGo-ERP measures (i.e., NoGo – Go). This heterogeneity between studies hinders comparisons 
between and conclusions from the studies; more standardization would increase the comparability 
between studies and would be desirable. 
In the Go/NoGo task (Fig. 1), participants are asked to respond to some stimuli (‘Go’-
trials) and to refrain from responding to other stimuli (‘NoGo’ trials). Due to the usually large 
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proportions of Go-trials, the participants develop a predominant tendency to respond that places 
high demands on executive processes of action restraint on NoGo-trials (Eigsti et al., 2006; 
Lange et al., 2014; Lange and Eggert, 2015). As displayed in Table 3, NoGo-P3 amplitudes were 
repeatedly reported to be attenuated in PD patients (Beste et al., 2009a; Bokura et al., 2005; 
Osawa et al., 2005; Pulvermüller et al., 1996; but see Beste et al., 2010). Note that Beste et al. 
(2009a), Bokura et al. (2005), and Pulvermüller et al. (1996) studied PD patients on their 
dopaminergic medication, whereas Beste et al. (2010) reported results that were obtained from 
PD patients off their dopaminergic medication. P3 latencies did not differ significantly between 
controls and PD patients in the two studies by Beste et al. (2009a, 2010). The difference between 
NoGo-P3 latencies minus Go-P3 latencies was enhanced in PD patients in the study by Beste et 
al. (2009a); however, the effect was confined to a version of the Go/NoGo task which involved 
semantic incompatibility between stimuli and responses (i.e., ‘STOP’ signaled Go-trials and 
‘PRESS’ signaled NoGo-trials), thereby posing particularly high demands on executive control. 
Moreover, Bokura et al. (2005) found prolonged NoGo-P3 latencies in PD patients, whereas Go-
P3 latencies did not differ from those observed in controls. 
Two ERP studies in PD patients employing Go/NoGo tasks revealed generally enhanced 
(i.e., more negative) N2 amplitudes in patients with PD (Beste et al., 2009a, 2010). These studies 
differ with regard to the precise N2 amplitude effects: While Beste et al. (2009a) found enhanced 
NoGo-N2 amplitudes in PD, the later study by Beste et al. (2010) reported unaltered NoGo-
minus-Go N2 amplitude differences in PD. Yet another study showed attenuated NoGo-minus-
Go N2 amplitude differences in PD (Bokura et al., 2005). Only one study found N2 latencies to 
be generally prolonged in PD patients (Beste et al., 2009a), whereas the NoGo-minus-Go N2 
latency differences appear to be unaltered in PD (Beste et al., 2009a; Bokura et al., 2005). 
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To conclude, the available studies assessing ERPs in Go/NoGo tasks yielded quite 
inconsistent findings, with the sole exception that four studies reported attenuated NoGo-P3 
amplitudes in PD. The only study that did not report attenuated NoGo-P3 amplitudes in PD 
patients looked at PD patients off their dopaminergic medication (Beste et al., 2010). A 
reasonable integration of these data across studies is, however, hampered by the heterogeneity of 
study designs and ERP measures. 
4.2 N2: conflict processing 
ERP indicators of conflict processing are usually examined in interference tasks in which 
automatic processes interfere with the selection of task-relevant responses. A prominent example 
is the Stroop task (Stroop, 1935). Here, the identity of a color word can interfere with the 
participants’ ability to name the color in which the word is displayed. For example, saying 
“green” (i.e., the task-relevant response) in response to the word “red” (triggering the task-
irrelevant response of saying “red”) written in green ink is more difficult compared to saying 
“green” in response to the word “green” written in green ink. In this latter case, the task-relevant 
response is identical to the task-irrelevant response. However, there is no ERP study of conflict 
processing in PD which relied on the Stroop task. Table 4 provides details of the available ERP 
studies which examined conflict processing using other interference tasks in PD. 
4.2.1 Simon task 
The Simon effect (Simon and Rudell, 1967) refers to the finding that spatially arranged 
responses to non-spatial stimulus features (such as shape, color etc.) are faster when the task-
irrelevant stimulus location and response location correspond compared to when they do not 
correspond (Leuthold, 2011). For instance, the participant is asked to press a key using the left 
hand when a blue stimulus occurs and to press another key using the right hand when a red 
stimulus occurs. Reactions are typically slower and more errors occur when the stimulus is 
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displayed contralaterally to the correct response hand. To date, only one study examined N2 
amplitudes in PD patients using a Simon task that reported reduced N2 amplitudes in PD 
(Praamstra and Plat, 2001). 
4.2.2 Flanker task 
In the flanker task (Eriksen and Eriksen, 1974; Kopp et al., 1996b; Seer et al., 2015), a 
central target stimulus (e.g. ‘>’) serves as the task-relevant stimulus which is surrounded by 
either congruent (‘> > > > >’) or incongruent (‘< < > < <’) task-irrelevant distractor stimuli, and 
the typical finding is that the automatic processing of task-irrelevant distractors interferes with 
the selection of task-relevant responses. Pronounced fronto-central N2 waveforms are observable 
on incongruent trials of the flanker task (Danielmeier et al., 2009; Folstein and Van Petten, 2008; 
Kopp et al., 1996b; Yeung et al., 2004). Fronto-central N2 waveforms are not only sensitive to 
congruency; they are also modulated by the congruency sequence across successive trials: N2 
amplitudes on incongruent trials are attenuated when the preceding trial was incongruent 
compared to when the preceding trial was congruent (Clayson and Larson, 2011a,b, 2012; Forster 
et al., 2011; Larson et al., 2012). This contextual modulation of N2 amplitudes has been 
attributed to an adaptation to the presence or absence of environmental conflicts, respectively 
(‘conflict adaptation’, Botvinick et al., 2001; for detailed discussion, see Egner, 2007). 
Inspection of Table 4 reveals that N2 amplitudes in the flanker task have repeatedly been 
found unaltered in chronically medicated PD patients (Praamstra et al., 1998; Stemmer et al., 
2007; Verleger et al., 2010; Willemssen et al., 2011). Similarly, congruency affects N2 
amplitudes normally in chronically medicated PD patients, with larger N2 amplitudes elicited on 
incongruent compared to congruent trials (Rustamov et al., 2013). However, one study found 
attenuated N2 amplitudes on incongruent trials in asymptomatic (and hence non-medicated) 
carriers of Parkin or PINK1 mutations who are considered to represent pre-clinical PD patients 
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(Verleger et al., 2010). In a similar vein, Willemssen et al. (2011; de novo | pre medication) found 
diminished N2 congruency effects in a group of newly diagnosed, drug-naive PD patients. 
Following the initiation of dopaminergic medication, N2 congruency effects no longer differed 
from that observed in a control group, potentially indicating that dopaminergic medication might 
remedy altered N2 congruency effects in drug-naive PD patients (Willemssen et al., 2011; de 
novo | post medication). Thus, the role of dopaminergic medication on N2 congruency effects in 
PD remains to be clarified in future studies. In particular, the effects of medication should be 
disentangled from learning effects; these two factors were (necessarily) confounded in the study 
by Willemssen et al. (2011) in which the patients were always drug-naive at initial testing, and 
always medicated at subsequent testing. 
Other ERP measures (N2 latencies: Praamstra et al., 1998; Rustamov et al., 2013; 
Willemssen et al., 2011; P3 amplitudes and latencies: Praamstra et al., 1998; Stemmer et al., 
2007; Willemssen et al., 2011; but see Verleger et al., 2013) were unaltered in PD when 
examined in flanker tasks. Overall, the evidence suggests that electrophysiological correlates of 
conflict processing are unaltered in medicated PD patients. However, it remains to be delineated 
whether N2 amplitude congruency effects provide a biomarker of nigro-striatal dopamine 
depletion in PD that is counteracted by dopaminergic medication. 
The contextual modulation of N2 amplitudes in the flanker task was found to be 
attenuated in medicated PD patients (Rustamov et al., 2013). Specifically, control participants 
showed the typical congruency sequence effect, i.e., substantially enhanced N2 amplitudes on 
incongruent trials when the preceding trial was congruent compared to when the preceding trial 
was incongruent. In contrast, N2 amplitudes were not differentially affected by the congruency 
sequence in PD patients. This finding may suggest that conflict adaptation is disturbed in PD; 
however, the functional significance of the congruency sequence effect is subject to debate (for 
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detailed discussion, see Rustamov et al., 2013). Another study (Rustamov et al., 2014) combined 
the flanker task with attentional set shifting such that central or peripheral stimuli were task-
relevant throughout short series of trials after which the spatial location of the task-relevant 
stimulus was altered back and forth. Control participants showed strong evidence for contextual 
modulation of ERPs across these series of trials. Specifically, N2 and P3 amplitudes on 
incongruent trials were enhanced on shift trials, and both amplitudes gradually decreased across 
repetition trials. In contrast, medicated PD patients did not show evidence for this contextual 
modulation of N2 and P3 amplitudes. Taken together, these two studies suggest that the analysis 
of contextual modulation of ERPs in the flanker task might be a more promising tool than the 
effects of flanker congruency on ERPs in PD. 
4.3 Ne/ERN: performance monitoring 
The flanker task has been frequently used to assess electrophysiological correlates of 
performance monitoring, most frequently the error negativity (Ne; Falkenstein et al., 1990; 
Falkenstein et al., 1991) or error-related negativity (ERN; Gehring et al., 1993). The Ne/ERN is 
an early negative deflection in response-synchronized ERP waveforms occurring at fronto-central 
scalp regions shortly after erroneous responses. Correct responses are also associated with a 
somewhat less pronounced response-synchronized negative waveform, which has been termed 
correct negativity (Nc) or correct-related negativity (CRN; Falkenstein et al., 2000; Vidal et al., 
2000). Erroneous responses further elicit positive response-synchronized waveform deflections 
which are referred to as error positivity (Pe; Falkenstein et al., 1990; Falkenstein et al., 1991). The 
Pe can be subdivided into an early, fronto-centrally distributed Pe and a late, parietally distributed 
Pe (Ullsperger et al., 2014a). Finally, a response-synchronized positive waveform deflection 
occurs after correct responses (Pc; e.g., Ito and Kitagawa, 2006; Olvet and Hajcak, 2012). 
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Table 5 shows the available Ne/ERN and Nc/CRN studies in PD. Attenuated Ne/ERN 
amplitudes in PD patients have been repeatedly reported (for an earlier overview, see Jocham and 
Ullsperger, 2009), most notably in the flanker paradigm (Beste et al., 2009b; Falkenstein et al., 
2001; Rustamov et al., 2014; Stemmer et al., 2007; Willemssen et al., 2008, 2009), but also in the 
Simon task (Falkenstein et al., 2001), in the Go/NoGo paradigm (Falkenstein et al., 2001), and in 
a lexical decision task (Ito and Kitagawa, 2006). Only two studies reported unaltered Ne/ERN 
amplitudes in PD (Holroyd et al., 2002; Verleger et al., 2013). It seems likely that the absence of 
statistically significant group differences is a result of the small samples sizes used in these 
studies. In fact, given the rather low statistical power associated with typical ERP studies in PD, 
the obtained pattern of results (11 out of 13 studies reporting significant group differences) is 
statistically more credible than one with 13 out of 13 studies reporting significant group 
differences (this latter pattern would rather suggest selective reporting of positive findings; 
Schimmack, 2012). In contrast, Ne/ERN latencies do not seem to be altered by PD (Beste et al., 
2009b; Ito and Kitagawa, 2006; Verleger et al., 2013; Willemssen et al., 2009). Falkenstein et al. 
(2001) found decreased Ne/ERN latencies in PD using a Simon task, but Ne/ERN latencies were 
unaltered in the same patients in a flanker task and in a Go/NoGo task. This pattern (no PD-
related Ne/ERN latency difference in four studies, latency decrease in one single task on a 
multiple-task study) is compatible with random error variance around a null effect. 
Nc/CRN amplitudes have been found unaltered in four studies (Beste et al., 2009b; 
Falkenstein et al., 2001; Ito and Kitagawa, 2006; Willemssen et al., 2008), whereas one study 
found enhanced Nc/CRN amplitudes in PD patients (Willemssen et al., 2009). Nc/CRN latencies 
were consistently found to be unaffected by PD (Beste et al., 2009b; Falkenstein et al., 2001; Ito 
and Kitagawa, 2006; Willemssen et al., 2009). Falkenstein et al. (2001) assessed late Pe 
amplitudes in PD patients using a flanker task, a Simon task, and a Go/NoGo task, and they did 
 
 
32 
 
not find differences between PD patients and control participants. However, Ito and Kitagawa 
(2006) reported attenuated early Pe and Pc amplitudes in PD patients, whereas early Pe and Pc 
latencies were normal. 
4.4 Ne/ERN and dopaminergic medication in PD 
The reviewed body of evidence reveals disturbed neural activities for performance 
monitoring in PD, as assessed by Ne/ERN amplitudes. However, additional work is required to 
dissect the relative effects of disease and dopaminergic treatment on performance monitoring in 
PD. It is well recognized that the relation between dopamine and performance follows an inverted 
U-shaped function, implying that both insufficient and excessive levels of dopamine impair 
performance on cognitive tasks (Cools and D'Esposito, 2011; Fallon et al., 2013; Gotham et al., 
1988). In early clinical stages of PD, the degeneration of dopamine-producing cells is most 
pronounced in the substantia nigra, leading to severe dopamine depletion in the dorsal striatum, 
whereas mesocortical dopamine projections as well as ventral cortico-striatal loops are less 
affected (see Introduction). Dopaminergic replacement therapy, administered to alleviate motor 
symptoms associated with the affected dorsal cortico-striatal loops, can at the same time impair, 
through overdosing, functions relying on otherwise intact prefrontal (Gotham et al., 1988) and 
ventral cortico-striatal loops (Cools, 2006). Thus, it remains a possibility that most of the relevant 
Ne/ERN findings occurred as a corollary of excessive levels of dopamine in the prefrontal cortex 
and/or in the ventral striatum in medicated PD patients, rather than consequent to dopamine 
depletion in the dorsal striatum (Rustamov et al., 2014). 
Inspection of Table 5 reveals that the majority of relevant results was obtained from 
medicated PD patients and may thus be confounded by excessive levels of dopamine in the 
prefrontal cortex and/or in the ventral striatum due to dopaminergic medication. However, there 
are three studies which examined Ne/ERN amplitudes in never-medicated PD patients (Beste et 
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al., 2009b; Stemmer et al., 2007; Willemssen et al., 2009) and three studies of PD patients who 
underwent a drug washout period (i.e., were tested after overnight withdrawal; Beste et al., 
2009b; Holroyd et al., 2002; Willemssen et al., 2008). Except the study by Holroyd et al. (2002), 
all these studies revealed attenuated Ne/ERN amplitudes in PD patients who were either drug-
naive or off dopaminergic medication, suggesting that insufficient levels of dopamine disturb 
neural activities for performance monitoring. 
Direct comparisons between PD patients on and off (or drug-naive) dopaminergic 
replacement therapy are scarce. Willemssen et al. (2008) studied 18 PD patients at early stages of 
the disease (mean UPDRS Part III on medication = 10.8; off medication = 14.8). These authors 
conducted intra-individual comparisons, and they counterbalanced the order of on-medication 
and off-medication testing. No effects of acute dopaminergic medication on Ne/ERN amplitudes 
could be discerned. The studies which compared drug-naive PD patients with chronically 
medicated PD patients did not report Ne/ERN amplitude differences between these groups, 
neither when the latter patients were on medication (Stemmer et al., 2007) nor when they were 
off medication (Beste et al., 2009b) during testing. In a more recent study, Siegert et al. (2014) 
found differential effects of dopaminergic therapy on task performance in a flanker task 
depending on the patients’ age and disease onset, supporting a dopamine overdose effect in 
younger patients with early onset of PD; these behavioral changes corresponded to the 
modulation of Ne/ERN amplitudes. 
4.5 NoGo-P3, N2, and Ne/ERN: conclusions and future directions 
From the reviewed body of evidence about ERP correlates of executive dysfunctioning in 
PD there is reasonably good evidence for attenuated NoGo-P3 amplitudes in medicated PD 
patients. The N2 data are much less clear-cut, but they point in the direction that N2 amplitudes 
might be attenuated in individuals at risk for developing PD (i.e., pre-symptomatic carriers of 
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gene mutations associated with PD) as well as in drug-naive, but not in chronically medicated PD 
patients. Thus, N2 amplitudes have the potential to provide a biomarker of nigro-striatal 
dopamine depletion in PD. An analysis of the contextual modulation of N2 amplitudes in the 
flanker paradigm is a promising candidate for further experimentation in that direction. Overall, 
the Ne/ERN amplitude findings in PD provide the most compelling evidence for a disturbance in 
the neural substrates of executive functions in PD (Fig. 3, right panel). Taken together, the 
reviewed Ne/ERN data imply that both insufficient and excessive levels of dopamine impair 
performance monitoring in PD. We depict our main conclusions from this review of the literature 
in Fig. 4 (left panel). 
5 Approaches exploring ERPs in other cognitive domains 
5.1 Language 
Language processing in PD has been investigated against the background of the 
influential declarative/procedural model of language (Ullman, 2001). The model holds that the 
(declarative) mental lexicon is represented in temporal cortical areas while the (procedural) 
mental grammar relies on the integrity of frontal cortex and the basal ganglia. In accordance with 
this idea, patients suffering from PD appear to have difficulties in syntactic, but not semantic 
language processing (Friederici et al., 2003). ERP analysis has been proven to be highly useful in 
generating evidence for this dissociation. Compared to sentences in which the final word meets 
the individual’s expectations (e.g., “The shirt has been ironed.”), when the final word of a 
sentence is semantically incongruent (e.g., “The thunderstorm has been ironed.”), these 
incongruent word stimuli typically elicit a centroparietal negativity, the N400 (Kutas and 
Hillyard, 1980). In contrast, syntactical violations (e.g., the “to” in “The mother induced to watch 
the children.”) are followed by a centroparietal positivity, the P600, in comparison to 
syntactically correct events (e.g., the “to” in “The mother agreed to adopt the child.”) (Osterhout 
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and Holcomb, 1992). Hence, the N400 and P600 can be regarded as electrophysiological 
correlates of semantic and syntactic processing, respectively. In a group of medicated, non-
demented PD patients, the N400 was found to be unaltered, while the P600 appeared to be 
modulated by the disease (Friederici et al., 2003). Furthermore, while the P600 amplitude did not 
significantly differ as a function of syntactic correctness in PD, early automatic parsing processes 
(as indexed by the Early Left Anterior Negativity, ELAN) seemed to be largely preserved. These 
analyses were taken to suggest that syntactic rather than semantic and late integrational rather 
than early automatic processes are affected by PD. Note, however, that these dissociations are 
based on the absence of a significant P600 effect in PD, and not on a significant reduction of the 
P600 effect in PD patients when compared to healthy controls. Future studies involving larger 
sample sizes are required to establish the absence of P600 effects as a correlate of altered 
syntactic integration in PD patients and dissociate the influence of PD pathology from the effects 
of dopaminergic medication on language processing (De Letter et al., 2012). 
5.2 Memory 
In the section on novelty processing, we have already discussed the observation that PD 
patients lack the typical von Restorff effect (i.e., better memory for a word when it is written in a 
novel font), possibly as a result of a failure to allocate attentional resources to the novel 
information (Schomaker et al., 2014). This finding is compatible with further studies on the ERP 
correlates of memory processes in PD. Kida et al. (2007) presented patients and healthy controls 
with a series of unfamiliar faces and contrasted ERPs elicited by the first presentation of a face 
with the potentials evoked by the same stimulus when it was repeated later in the series. Healthy 
controls showed an enhanced positive waveform between 300 and 500 ms after stimulus 
presentation for repeated compared to novel faces. This ERP repetition positivity was absent in 
patients with PD, which may point to a disease-related deficit in recognition memory. In support 
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of this conclusion, response latency and accuracy data collected in this study revealed that PD 
patients had difficulties judging new stimuli as being new. The same recognition deficit could be 
found in a similar study using auditory presentation of words (Minamoto et al., 2001). The PD-
related memory impairment was accompanied by reduced amplitudes of a negative waveform 
peaking in the same latency range as the potential analyzed by Kida et al. (2007). Hence, N400-
like waveforms appear to reflect altered recognition memory in PD, a conclusion that is further 
corroborated by a study of Tachibana et al. (1999). Here, in comparison to the first presentation, 
the second presentation of a word resulted in attenuated N400-like amplitudes in healthy controls, 
both when the repetition occurred on successive trials and when up to 77 words were interspersed 
between the first and the second presentation. In PD patients, however, this ERP repetition effect 
was only present when the word was directly repeated and had already vanished when the 
repetition occurred after five words. Together, these three studies on ERP waveform modulations 
in the N400 time range point to a consistent alteration in memory processes in PD, specifically 
when it comes to the integration of incoming stimulus information with the recent memory 
context. 
In addition, the results presented by Lee et al. (2010) point to a potential deficit in visual 
working memory in PD patients. In this study, participants were asked to remember the 
orientation of objects appearing on one side of the screen. After a retention interval of 800 ms, 
the display was presented again and participants had to indicate whether the objects’ orientation 
had changed. During the retention interval, contralateral delay activity (CDA) was measured as a 
sustained negativity over posterior electrodes contralateral to the side of stimulus presentation. 
The CDA amplitude likely reflects the number of items held in working memory (Luria et al., 
2016; Vogel and Machizawa, 2004). In contrast to healthy controls, the CDA amplitude was 
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attenuated in PD patients, possibly indicating that PD patients have difficulty retaining all 
relevant information in visual working memory. 
5.3 Feedback evaluation in decision-making 
Value-based decision-making in PD patients is an interesting issue due to the close link 
between this cognitive function and dopaminergic brain networks (Rangel et al., 2008). While PD 
patients have been repeatedly demonstrated to be impaired on tasks that require adaptive 
decisions among a set of options, this deficit does not seem to be a general one (Ryterska et al., 
2013). First, decision-making in PD typically improves when patients are tested off their 
dopaminergic medication (e.g., Cools et al., 2003). Second, PD does not seem to affect all stages 
of the decision-making process to the same extent. Efficient decision-making requires, as a first 
step, the representation and valuation of a set of possible options before the individual has to 
choose an option based on the assigned values. Then, the outcomes of the chosen action need to 
be evaluated in order to update value representations for future decisions (Rangel et al., 2008). A 
recent meta-analysis suggests that PD-related decision-making deficits can largely be attributed 
to alterations in this latter process of feedback evaluation (Ryterska et al., 2013). 
The ERP technique offers some possibilities to further investigate this hypothesis at the 
cortical level. In a study by Mapelli et al. (2014), for example, ERPs elicited by positive and 
negative feedback stimuli in a gambling task have been compared between HC and PD patients 
on medication. In accordance with multiple studies using similar paradigms, negative outcomes 
evoked a relative fronto-central negativity about 300 ms after stimulus onset in HC. This so-
called feedback-related negativity (FRN; Miltner et al., 1997) was absent in the patient group, 
indicating that neural responses from PD patients failed to distinguish between positive and 
negative outcomes. This evidence for impaired negative feedback processing in PD may also 
account for the finding that task performance in this study did not markedly improve over time in 
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PD patients (Mapelli et al., 2014). In a further study, the PD-related reduction in FRN amplitude 
was found to be especially pronounced in patients showing elevated levels of apathy (Martínez-
Horta et al., 2014). 
The PD-related insensitivity to feedback valence does not only become evident after 
outcome presentation of feedback stimuli, but also in anticipation of these events. The stimulus 
preceding negativity (SPN) over fronto-central electrode sites is typically enlarged when the 
occurrence of motivationally significant events can be expected (van Boxtel and Böcker, 2004). 
This notion could also be supported by Mattox et al. (2006), who found SPN amplitudes to be 
larger prior to high reward values as compared to low reward values in a sample of HCs. In PD 
patients, however, this effect was reversed, suggesting severe alterations in anticipation of 
outcome valence in PD. 
Although there is a surprisingly small number of ERP studies on decision-making in PD, 
these studies paint a consistent picture of PD-related impairment at the stage of outcome 
evaluation (see also Frank et al., 2004). Future studies need to contrast different stages of the 
decision-making process and to disentangle effects of the primary disease pathology and 
dopaminergic medication. 
5.4 Emotion 
ERP correlates of emotional processing in PD patients were first examined by Wieser et 
al. (2006) who asked their participants to rate the emotional arousal associated with positive and 
negative visual stimuli. Compared to healthy controls, PD patients rated highly arousing stimuli 
as well as pictures of negative valence as less exciting. The early parietal negativity (EPN), an 
ERP waveform developing 200 ms after stimulus onset, could be demonstrated to vary with 
emotional arousal, but this potential did not reveal any alteration in the PD group. These results 
are quite consistent with a study by Dietz et al. (2013), showing that, in the absence of any early 
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ERP alterations, PD patients rated unpleasant stimuli as less arousing in comparison to pleasant 
pictures and in comparison to healthy controls. This finding was accompanied by a selective PD-
related reduction of a late centro-parietal positivity in response to unpleasant words. Interestingly, 
this pattern of decreased emotional reactivity to aversive stimulation could be linked to patients’ 
apathy scores and hence to one of the most prevalent non-motor symptoms in PD (Aarsland et al., 
2007). 
When PD patients are explicitly required to discriminate the valence of emotional stimuli, 
PD-related differences can also be identified at earlier stages of information processing. 
Participants in a more recent study by Wieser et al. (2012) were asked to distinguish different 
emotional categories from facial expressions. EPN was found to be enhanced for emotional faces 
when compared to neutral faces in healthy controls, but not in patients with PD. However, 
emotion recognition rates did not differentiate between the two groups. Auditory ERP paradigms 
have also been used to investigate PD patients’ perception of emotional speech. By using sadly 
spoken and happily spoken target words in an oddball procedure, Schröder et al. (2006) were able 
to show that patients had difficulties discriminating emotional prosody. This performance 
decrement was also mirrored on the level of the ERPs with decreased P3b amplitude in PD 
patients for happy but not for sad targets. A further study by Garrido-Vásquez et al. (2013) 
demonstrated that when healthy controls were required to detect different emotions from prosody, 
the amplitude of the P2 waveform (Kopp et al., 2007; Kopp and Wessel, 2010) decreases for fear 
and disgust prosody compared to neutral prosody. While the same pattern could be observed in 
PD patients who showed predominantly right-sided motor symptoms, no disgust effect on P2 
amplitude could be observed in patients showing predominantly left-sided motor symptoms. 
While providing additional ERP evidence for altered early processes of emotion recognition in 
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PD, this study also highlights the significance of asymmetric neuronal degeneration for 
understanding PD-related cognitive changes. 
In sum, it appears that ERP correlates of emotional processing in PD are less sensitive to 
emotional content when patients are explicitly instructed to discriminate emotional content. 
However, this lack of sensitivity is not consistently associated with poorer emotion recognition 
performance. Moreover, ERP evidence suggests that PD patients are less aroused by emotional 
stimuli than healthy controls and future research in this area is needed to establish the role of this 
phenomenon in understanding PD-related symptoms of apathy and depression. 
6 General conclusions, open questions, and directions for future research 
We reviewed the available literature investigating cognitive ERPs in PD. The main 
findings are summarized in Table 6. We found that by-and-large two independent lines of ERP 
research were pursued in PD. Their results are in general agreement with the ‘dual-syndrome 
hypothesis’ of cognitive dysfunction in PD (Kehagia et al., 2013; Robbins and Cools, 2014), and 
this conclusion constitutes a highlight of the reviewed literature. The ‘dual-syndrome hypothesis’ 
defines one cluster of cognitive dysfunction in PD that comprises non-demented PD patients with 
mild cognitive impairment who primarily show deficits in executive functions. PD-related 
executive dysfunctions likely reflect fronto-striatal alterations (Dirnberger and Jahanshahi, 2013), 
and they are sensitive to dopaminergic medication (Kehagia et al., 2013). There is reasonably 
good evidence for attenuated NoGo-P3 amplitudes in medicated PD patients, and less clear-cut 
evidence which points to reduction of conflict-N2 amplitudes in individuals at risk for developing 
PD (as identified by gene mutations associated with PD) as well as in drug-naive, but not in 
chronically medicated, PD patients. In addition, the reviewed data on consistently attenuated 
Ne/ERN amplitudes imply that both insufficient and excessive levels of dopamine impair 
performance monitoring in PD (cf. Fig. 4, left panel). 
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The second cluster of PD patients show decline in non-frontal cognitive functions (such as 
visuospatial abilities, Miller et al., 2013), and the presence of these cognitive dysfunctions during 
early stages of the disease predicts rapid progression to PDD (Robbins and Cools, 2014; 
Williams-Gray et al., 2009). PDD is a form of dementia which has been attributed to the 
degeneration of temporal and parietal cortical areas and the nucleus basalis of Meynert 
(Gratwicke et al., 2015; Kehagia et al., 2013). We found good evidence for prolonged P3b 
latencies in PDD, suggesting prolonged duration of stimulus evaluation. We also found a lack of 
consistent effects of dopaminergic medication on P3b latency prolongation in PDD. Taken 
together, prolonged P3b latencies in PDD do not seem to result from PD-specific 
neurodegeneration, i.e., from nigro-striatal dopamine depletion. This conclusion is further 
corroborated by the fact that P3b latency prolongation is known to occur in other forms of 
dementia as well, such as for example in AD. Thus, prolonged P3b latency might serve as a 
biomarker of the presence of dementia in PD, but this lacks nosological specificity. The MMN 
data are much less clear-cut, but they indicate that the MMN amplitude may be attenuated in 
PDD in a nosologically specific manner, suggesting specifically disturbed sensory processing in 
Lewy-body related neurodegeneration. One of the reasons why P3b latency prolongation and 
MMN amplitude attenuation may differ with regard to their nosological specificity can be sought 
in the neural origins of these scalp-recorded ERPs: The P3b has its origins in posterior cortical 
regions, with no contribution from prefrontal regions, whereas the MMN is generated from the 
auditory cortices bilaterally, but there is an additional contribution from the right lateral 
prefrontal cortex (see Introduction). 
In conclusion, the reviewed research suggests that ERPs might serve as useful biomarkers 
of different facets of cognitive impairment in PD. Attenuated amplitudes of the NoGo-P3, the 
conflict-N2, and, most promisingly, the Ne/ERN may indicate changes of executive functioning 
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in PD, which possibly relate to early nigro-striatal and later mesocortical dopamine depletion. In 
contrast, prolonged P3b latencies and attenuated MMN amplitudes appear to be sensitive to the 
presence of PDD. In search of biomarkers for PDD, previous studies have already demonstrated 
the usefulness of cerebrospinal fluid levels of amyloid-β and total and phosphorylated tau to 
discriminate patients with PDD from PD patients without dementia (see Aarsland, 2016; 
Delgado-Alvarado et al., 2016; Irwin et al., 2013; Svenningsson et al., 2012 for review). In 
combination with these markers, the electrophysiological indicators identified here could 
contribute to a multi-modal approach of disease diagnosis and prediction (Aarsland, 2016; 
Delgado-Alvarado et al., 2016; Svenningsson et al., 2012).  
Despite the progress that has been made in the field that we document here for the first 
time in its entirety (see Růžička and El Massioui, 1993, for an earlier review), many questions 
remain open for future research. For example, further studies are required to clarify whether 
ERPs can make useful contributions to the routine assessment of cognitive symptoms. As 
correlates of cognitive processes, ERPs may mirror more accurately than conventional 
neuropsychological tests which specific cognitive functions are disturbed in PD and PDD. In this 
respect, it is important that the ERP technique offers unique solutions to the assessment of 
cognitive functions, particularly in patients with movement disorders (e.g., Lange et al., 2016a; 
Rustamov et al., 2013, 2014) or motor neuron disease (e.g., Lange et al., 2016b; Seer et al., 
2015), where motor deficits are likely confounding the results of neuropsychological testing. In 
these disorders, ERPs may also facilitate the monitoring of cognitive change and the evaluation 
of new treatments for cognitive impairment. 
In addition, ERPs might help identify meaningful subgroups of PD patients (e.g., patients 
with PDD; Luck et al., 2011). A promising approach to this problem is to use ERP data to 
classify individuals, e.g., as members of a group of patients with a given disease or as members 
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of a group without that disease. This technique has been applied to classify patients with 
schizophrenia with some success, particularly when using multiple paradigms and outcome 
variables (Laton et al., 2014; Neuhaus et al., 2011). 
Finally, ERPs can be even more useful if they predict individual differences in disease 
progression and/or treatment response. For example, it would be very interesting to know 
whether P3b latency provides a biomarker predicting – at the earliest stages of the disease – 
progression to dementia in PD patients at later stages of the disease. Another remarkable 
possibility is that NoGo-P3, N2, and/or Ne/ERN amplitude measures may serve to titrate the 
treatment dose of dopaminergic therapy in individual PD patients. 
However, there are limitations in the ERP technique as currently applied to the study of 
PD. These limitations require attention before ERPs can be considered a valuable contribution to 
care for PD patients. Due to small sample sizes, the statistical power of single studies is in most 
cases insufficient to detect the effects of interest. Sufficient statistical power and highly reliable 
results are best ensured by conducting multi-site, large-N studies (e.g., N > 500). It has been 
demonstrated by a number of multi-site, large-N studies in psychiatric research that the technique 
ERP is feasible for these types of studies (e.g., Hesselbrock et al., 2001; Light et al., 2015; Olincy 
et al., 2010; Turetsky et al., 2015; see also Luck et al., 2011). An essential prerequisite for 
conducting multi-site, large-N studies is to standardize assessment protocols adequately. To date, 
studies vary widely with regard to stimulus materials, recording procedures, response modes, and 
analysis methods. Standardized assessment protocols would not only be required for the 
conductance of multi-site, large-N studies; they are also a prerequisite for implementing ERPs in 
clinical practice. The assessment of sensory evoked potentials, which are used as objective 
measures of sensory function in clinical practice, may serve as an example of a successful clinical 
implementation of the ERP technique (Chiappa, 1997; Duncan et al., 2009). 
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The majority of previous ERP studies in PD relied on simple group comparisons between 
small groups of PD patients and matched controls, often aiming to investigate whether a 
particular ERP waveform is ‘normal’ or altered in PD. To benefit from the potential of ERPs as 
diagnostic tools, it is necessary to address more refined questions, such as whether ERPs are 
more state-like (i.e., sensitive for intra-individual fluctuations) or more trait-like (i.e., stable 
across intra-individual fluctuations) biomarkers of cognitive impairment in PD (Luck et al., 
2011). The evidence to date suggests that prolonged P3b latencies should be considered as a trait-
like marker of cognitive decline to dementia in PD, found to be largely independent of 
dopaminergic fluctuations. However, it still remains to be delineated to what degree NoGo-P3, 
N2, and/or Ne/ERN amplitude attenuation in PD are sensitive to dopaminergic fluctuations, i.e., 
to the depletion of dopamine in PD and to its substitution by dopaminergic therapy. Intra-
individual (within-subjects) designs investigating the impact of different types and doses of 
dopaminergic medication may help clarify the relationship between dopamine and ERPs of 
executive processes in PD. These studies should preferably be conducted in a placebo-controlled 
and counterbalanced way to eliminate some of the confounding factors in previous medication 
studies on the ERP correlates of PD. Fig. 4 (right panel) shows testable predictions for intra-
individual designs which can be derived from the reviewed data. 
Advances in surgical treatment of PD, namely DBS, facilitate investigating the 
neuroanatomical basis of ERPs measured in patients with PD. Similar to intra-individual 
comparisons of dopaminergic medication states as proposed above, within-subjects comparisons 
can be performed on and off stimulation states (e.g., Gerschlager et al., 2001). Such studies may 
help to reveal the role of the stimulated basal ganglia nuclei for specific cognitive processes and 
their ERP correlates. In addition, DBS allows for electrophysiological recordings directly from 
the stimulated site (i.e., the recording of local field potentials; e.g., Siegert et al., 2014) and thus 
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provides the possibility to examine electrophysiological correlates of cognitive processes at the 
level of neuronal populations (Münte et al., 2008). 
In conclusion, we think that the progress that has been made in the reviewed field 
represents a currently widely underrecognized scientific achievement. Based on quality-assured 
(Luck et al., 2011) and source-resolved (Light and Makeig, 2015) ERP measures, the pursuance 
of multi-site, large-N studies as well as of longitudinal studies will move the field one step 
forward toward the clinical utility and application of ERPs in PD. 
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Table 1 
Overview of the studies assessing P3b measures using oddball paradigms in patients with Parkinson’s disease. 
Study 
N 
med HY age dur dem 
oddball 
task 
stimulus 
modality 
% 
target 
response 
mode 
P3b 
PD HC latency amplitude 
Antal et al. (1996)* 20 20 on 1.9 63.2 6.7 no 2stim vis mix press → ↓ 
Antal et al. (2000) 20 20 on 2.3 65.3 4.8 no 2stim vis 20 press ↑ ↓ 
Aotsuka et al. (1996) 21 - - - - - no 2stim aud 20 - ↑ ↓ 
Bathien et al. (1996) 
cognitively unimpaired 15 10 - 2.1 64.5 10.0 no 2stim vis 20 press → → 
Bathien et al. (1996) 
cognitively impaired 10 10 - 3.1 70.6 13.8 no 2stim vis 20 press ↑ → 
Bocquillon et al. (2012) 15 15 on 1.5 59.2 4.8 no 3stim vis 8 press ↑ → 
Chen et al. (2006) 27 27 on - 63.3 40.1 no 2stim aud 15.4 press → → 
Chia et al. (1995) 22 16 on 2.4 67.2 7.4 mix 2stim aud 15 recognize ↑ - 
Ebmeier et al. (1992)* 16 16 on 2.4 69.0 9.3 no 2stim aud 12.5 mix → - 
Elwan et al. (1996) 43 37 off 2.6 61.8 2.4 mix 2stim aud 30 press ↑ - 
Fogelson et al. (2011) 8 8 on 2.3 61.6 6.8 no 2stim vis 15 press ↓ ↑ 
Gaudreault et al. (2013) 15 16 on 2.2 63.1 5.4 no 3stim vis 15 press → → 
Georgiev et al. (2015) 14 13 
on/ 
off 1.8 60.4 3.5 no 3stim mix 15 count → → 
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Gerschlager et al. (2001) 8 8 off - 66.9 14.5 no 2stim aud 20 press ↑ → 
Gil et al. (1989) 24 24 mix - 63.8 4.6 mix 2stim aud 33 count ↑ ↓ 
Goodin & Aminoff (1987) 
dem 14 40 on 2.5 71.4 4.8 yes 2stim aud 14 count ↑ - 
Goodin & Aminoff (1987) 
non-dem 14 40 on 2.7 67.2 5.0 no 2stim aud 14 count → - 
Graham et al. (1990) - - off - - - no 2stim aud - press → → 
Green et al. (1996) 20 20 off 1.3 54.1 - no 2stim aud 14 press → ↑ 
Hanafusa et al. (1991) 8 29 - - 74.5 - yes 2stim aud 20 press ↑ - 
Hansch et al. (1982) 20 20 on - 64.3 10.2 mix 2stim aud 15 count ↑ → 
Hautecœur et al. (1991) 
dem 28 20 - 2.3 72.4 3.3 yes 2stim aud 15 count ↑ ↓ 
Hautecœur et al. (1991) 
non-dem 55 20 - 2.0 69.0 3.1 no 2stim aud 15 count → → 
Hayashi et al. (1993) 53 - - - - - - 2stim - - press ↑ - 
Hayashi et al. (1996) 
HY stage 2 11 12 on 2.0 54.4 5.4 mix 2stim aud 20 count → - 
Hayashi et al. (1996) 
HY stage 3 18 13 on 3.0 60.8 6.0 mix 2stim aud 20 count ↑ - 
Hozumi et al. (2000) 15 13 on 2.1 65.4 5.6 no 3stim aud 20 count → → 
Iijima et al. (2000) 20 55 on 2.2 63.1 4.9 no 2stim aud 20 count ↑ → 
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Ito (1994) 
dem 13 18 on - 66.0 - yes 2stim som 20 count ↑ → 
Ito (1994) 
non-dem 11 18 on - 65.0 - no 2stim som 20 count → → 
Jiang et al. (2000) 12 9 on 2-3 66.3 6.3 no 2stim aud 20 count ↑ ↓ 
Karayanidis et al. (1995) 16 15 on 1-2 67.2 3.0 no 2stim aud 7 press → → 
Katsarou et al. (2004) 45 40 on 2-3 59.3 6.1 no 2stim aud 20 count ↑ → 
Kim et al. (1995) 16 15 off 2.1 62.6 2.3 no 2stim aud - count ↑ - 
Kurita et al. (2010)* 17 20 on 3.7 73.9 9.2 yes 2stim mix 20 count ↑ - 
Lagopoulos et al. (1998b) 15 15 mix 1-3 60.1 5.1 no 2stim aud 15 press → → 
Lagopoulos et al. (1998a) 15 50 - - - - no 2stim aud - press ↑ → 
Li et al. (2005) 22 23 on 2.6 64.2 6.3 - 3stim vis 20 press ↑ ↓ 
Lopes et al. (2014) 43 33 on 2.3 63.1 7.0 mix 2stim aud 20 count ↑ - 
Lukhanina et al. (2009) 61 21 off 2.4 61.4 7.6 mix 2stim aud 22.5 count ↑ → 
Lukhanina et al. (2008) 35 18 - 1.5-3 61.1 4.5 mix 2stim aud 20 count ↑ → 
Morita et al. (2005) 18 18 - 3.5 67.3 9.9 no 2stim vis 20 mix ↑ → 
Nojszewska et al. (2009) 42 14 on 2.5 65.8 7.8 no 2stim aud 20 count → - 
Oishi et al. (1996) 10 10 off 2-3 63.0 - no 2stim aud 20 count ↑ → 
O'Donnell et al. (1987) 16 11 on 2.6 65.8 6.3 mix 2stim aud 15 count ↑ - 
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Philipova et al. (1997) 17 17 on - 54.0 2.9 no 2stim aud 60 count → ↓ 
Pirtošek et al. (2001) 19 8 off 2.5 67.0 3.0 no 3stim aud 15 press → → 
Potagas et al. (2003) 53 20 on 2.5 67.7 7.8 no 2stim vis 20 press ↑ ↑ 
Prabhakar et al. (2000) 25 25 off - 58.2 1.8 no 2stim aud - count → - 
Prasher & Findley (1991) 27 27 off 1-2 56.0 2.0 mix 2stim aud 30 press → - 
Raudino et al. (1997) 49 39 on - 65.7 4.9 mix 2stim aud 20 count → ↓ 
Rumbach et al. (1993) 26 32 on 2.2 66.0 4.2 mix 2stim aud 20 press ↑ → 
Růžička et al. (1994) 8 9 off 2.5 59.4 8.3 no 2stim aud 20 count → → 
Sagliocco et al. (1997) 17 17 on 2.1 61.9 31.3 no 2stim vis 20 count → → 
Sarikaya et al. (2014) 38 39 on 1.9 58.8 5.8 no 2stim aud 20 count ↑ → 
Sartucci et al. (1990) 21 13 mix 2.4 61.8 6.9 mix 2stim aud 25 count → → 
Smolnik et al. (2002) 13 13 off - 67.0 8.4 no 2stim aud 20 press → → 
Sohn et al. (1998) 
off 19 13 off 2.1 64.0 2.3 no 2stim aud - count ↑ - 
Sohn et al. (1998) 
on 18 13 on 2.6 61.0 3.6 no 2stim aud - count ↑ - 
Stamenović et al. (2005) 30 15 off 1.4 61.3 - no 2stim aud - count ↑ - 
Stanzione et al. (1991) 18 20 off 2.3 64.9 3.0 no 2stim aud 20 count ↑ - 
Stanzione et al. (1998) 44 31 off 2.1 60.7 2.3 no 2stim aud 20 count → → 
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Tachibana et al. (1992) 
dem 6 37 on 3.0 70.7 5.4 yes 3stim vis 19 press ↑ → 
Tachibana et al. (1992) 
non-dem 25 37 on 2.3 66.0 2.7 no 3stim vis 19 press → → 
Tachibana et al. (1997) 29 19 mix 2.4 63.9 6.0 no 2stim vis 20 press ↑ → 
Tanaka et al. (2000) 
dem 7 11 on 3.3 64.1 7.7 yes 2stim aud 20 count ↑ → 
Tanaka et al. (2000) 
non-dem 15 11 on 2.4 64.1 5.6 no 2stim aud 20 count → ↑ 
Toda et al. (1993) 
dem 9 15 on 2.4 67.9 - yes 3stim vis 19 press ↑ → 
Toda et al. (1993) 
non-dem 26 15 on 2.4 67.2 - no 3stim vis 19 press → → 
Tsuchiya et al. (2000) 18 35 on 2.2 64.4 5.5 no 3stim aud 20 press → ↓ 
Vieregge et al. (1994) 14 16 on 2.2 61.0 5.0 no 2stim aud 14 press → → 
Wang et al. (1999) 38 24 on 2.5 65.8 7.4 no 3stim vis 20 press → → 
Wright et al. (1996)* 17 28 mix 2.0 62.5 6.8 no 2stim aud 25 mix → → 
Zeng et al. (2002)* 18 16 on 1.7 63.9 4.6 no mix mix 20 press → ↑ 
Note. For studies reporting a within-subject manipulation of task parameters (e.g., visual vs. auditory; on vs. off medication), P3b results 
were evaluated based on the mean across different conditions. These studies are marked with an asterisk (*) in the table. 
2stim = two-stimulus oddball task; 3stim = three-stimulus oddball task; aud = auditory; dem = demented; dur = disease duration in years; 
HC = healthy controls; HY = mean score obtained on the Hoehn & Yahr scale; med = antiparkinsonian medication state; mix = mixed; 
non-dem = non-demented; PD = patients with Parkinson’s disease; vis = visual; ↑ indicates larger values of the respective measure in PD; 
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↓ indicates smaller values of the respective measure in PD; → indicates that no significant difference was found in the respective measure 
between PD and HC; - indicates that the measure could not be extracted from the respective study, either because it was not reported, or 
because the full version of the article could not be accessed.
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Table 2 
Overview of the studies investigating novelty processing and deviance detection in patients with Parkinson’s disease. 
Study 
N 
med HY age dur dem 
stim 
mod 
% 
tar 
% 
distr 
task 
dim 
distr 
type 
resp 
mode   PD HC 
 
P3a  
three-stimulus 
oddball task 
 latency amplitude 
Bocquillon 
et al. (2012) 15 15 on 1.5 59.2 4.8 no vis 8 8 size 
dev 
shape press → → 
Gaudreault 
et al. (2013) 15 16 on 2.2 63.1 5.4 no vis 15 15 pos 
novel 
shape press → → 
Georgiev et 
al. (2015) 
on | aud 14 13 on 1.8 60.4 3.5 no aud 15 15 freq noise count → → 
Georgiev et 
al. (2015) 
on | vis 14 13 on 1.8 60.4 3.5 no vis 15 15 size 
dev 
shape count → → 
Georgiev et 
al. (2015) 
off | aud 14 13 off 1.8 60.4 3.5 no aud 15 15 freq noise count → → 
Georgiev et 
al. (2015) 
off | vis 14 13 off 1.8 60.4 3.5 no vis 15 15 size 
dev 
shape count → → 
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Hozumi et 
al. (2000) 15 13 on 2.1 65.4 5.6 no aud 20 10 freq 
dev 
freq count ↓ → 
Li et al. 
(2005) 22 23 on 2.6 64.2 6.3 - vis 20 20 shape 
dev 
shape press → ↓ 
Pirtošek et 
al. (2001) 19 8 off 2.5 67 3 no aud 15 15 freq 
dev 
freq press → → 
Tachibana 
et al. (1992) 
non-dem 25 37 on 2.3 66 2.7 no vis 19 19 shape 
dev 
shape press → → 
Tachibana 
et al. (1992) 
dem 6 37 on 3 70.7 5.4 yes vis 19 19 shape 
dev 
shape press → → 
Toda et al. 
(1993) 
non-dem 26 15 on 2.4 67.2 - no vis 19 19 shape 
dev 
shape press → → 
Toda et al. 
(1993) 
dem 9 15 on 2.4 67.9 - yes vis 19 19 shape 
dev 
shape press → → 
Tsuchiya et 
al. (2000) 18 35 on 2.2 64.4 5.5 no aud 20 15 freq 
novel 
sound press ↑ ↓ 
Wang et al. 
(1999) 38 24 on 2.5 65.8 7.4 no vis 20 20 shape 
dev 
shape press → ↓ 
Wang et al. 
(2000) 16 22 on 1.9 62.5 2.3 no vis 20 20 shape 
dev 
shape press → ↓ 
 
 
92 
 
Zeng et al. 
(2002) 
aud 18 16 on 1.7 63.9 4.6 no aud 20 16 words 
novel 
noise press ↑ → 
Zeng et al. 
(2002) 
vis 18 16 on 1.7 63.9 4.6 no vis 20 16 words 
novel 
figure press ↑ → 
 
P3a  
distraction 
paradigm 
              latency amplitude 
Solís-
Vivanco et 
al. (2011) 
on 25 20 on - 55.1 4.9 no aud 50 10 durat 
dev 
freq press → ↓ 
Solís-
Vivanco et 
al. (2011) 
off 17 20 off - 56.9 2.4 no aud 50 10 durat 
dev 
freq press → ↓ 
Solís-
Vivanco et 
al. (2015) 
HY stage 1 28 24 mix 1 56.2 3 no aud 50 10 durat 
dev 
freq press → → 
Solís-
Vivanco et 
al. (2015) 
HY stage 2 14 24 mix 2 57.2 5.3 no aud 50 10 durat 
dev 
freq press → ↓ 
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Solís-
Vivanco et 
al. (2015) 
HY stage 3 13 24 on 3 64.9 10 no aud 50 10 durat 
dev 
freq press → ↓ 
 
MMN  
irrelevant oddball 
sequence 
 latency amplitude 
Brønnick et 
al. (2010) 
non-dem 16 18 on 2 69.3 5.6 no aud - 10 - 
dev 
durat - → → 
Brønnick et 
al. (2010) 
dem 15 18 on 3.2 72.7 2.2 yes aud - 10 - 
dev 
durat - → ↓ 
Karayanidis 
et al. (1995) 16 15 on 1-2 67.2 3.0 no aud 7 7 
durat 
relev 
ear 
dev 
durat 
irrelev 
ear press → → 
Pekkonen et 
al. (1995) 13 11 on 1.2 64 3.5 no aud - 15 - 
dev 
freq - - ↓ 
Pekkonen et 
al. (2000) 16 11 - 1 - - no aud - - - 
dev 
durat - → → 
Vieregge et 
al. (1994) 14 16 mix 2.3 61 5 no aud 10 10 
durat 
relev 
ear 
dev 
durat 
irrelev 
ear press → → 
 MMN  
 
 
94 
 
distraction 
paradigm 
              latency amplitude 
Solís-
Vivanco et 
al. (2011) 
on 25 20 on - 55.1 4.9 no aud 50 10 durat 
dev 
freq press → → 
Solís-
Vivanco et 
al. (2011) 
off 17 20 off - 56.9 2.4 no aud 50 10 durat 
dev 
freq press → → 
Solís-
Vivanco et 
al. (2015) 
HY stage 1 28 24 mix 1 56.2 3 no aud 50 10 durat 
dev 
freq press → → 
Solís-
Vivanco et 
al. (2015) 
HY stage 2 14 24 mix 2 57.2 5.3 no aud 50 10 durat 
dev 
freq press → → 
Solís-
Vivanco et 
al. (2015) 
HY stage 3 13 24 on 3 64.9 10 no aud 50 10 durat 
dev 
freq press → → 
 
RON 
distraction 
paradigm 
 latency amplitude 
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Solís-
Vivanco et 
al. (2011) 
on 25 20 on - 55.1 4.9 no aud 50 10 durat 
dev 
freq press → → 
Solís-
Vivanco et 
al. (2011) 
off 17 20 off - 56.9 2.4 no aud 50 10 durat 
dev 
freq press → ↓ 
Solís-
Vivanco et 
al. (2015) 
HY stage 1 28 24 mix 1 56.2 3 no aud 50 10 durat 
dev 
freq press → → 
Solís-
Vivanco et 
al. (2015) 
HY stage 2 14 24 mix 2 57.2 5.3 no aud 50 10 durat 
dev 
freq press → → 
Solís-
Vivanco et 
al. (2015) 
HY stage 3 13 24 on 3 64.9 10 no aud 50 10 durat 
dev 
freq press → → 
Note. aud = auditory; dem = demented; dev = deviant; distr = distractor; dur = disease duration in years; durat = duration; freq = 
frequency; HC = healthy controls; HY = mean score obtained on the Hoehn & Yahr scale; irrelev = irrelevant; med = antiparkinsonian 
medication state; mix = mixed; MMN = mismatch negativity; non-dem = non-demented; PD = patients with Parkinson’s disease; pos = 
position; relev = relevant; resp mode = response mode; RON = reorienting negativity; stim mod = stimulus modality; tar = target; task 
dim = task-relevant dimension; vis = visual; ↑ indicates larger values of the respective measure in PD; ↓ indicates smaller values of the 
respective measure in PD; → indicates that no significant difference was found in the respective measure between PD and HC; - indicates 
that the measure could not be extracted from the respective study. 
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Table 3 
Overview of the studies investigating N2 and P3 measures using Go/NoGo tasks in patients with Parkinson’s disease. 
Study 
N 
med HY UPDRS age dur dem trial type 
N2 P3 
PD HC latency amplitude latency amplitude 
Beste et al. 
(2009a)a 
15 15 on - - 61.1 - no 
all trials ↑ ↑ → ↓ 
Go - → - → 
NoGo - ↑ - ↓ 
NoGo – Go → - 
comp: → 
incomp: ↑ 
- 
Beste et al. 
(2010) 
18 18 off - 14.6 60.5 - no 
all trials - ↑ → → 
NoGo – Go - → - → 
Bokura et al. 
(2005) 
13 14 on 2.9 - 71b 7.2 no 
Go - - → → 
NoGo - - ↑ ↓ 
NoGo – Go → ↓ - - 
Osawa et al. 
(2005) 
17 17 mix 2.1 - 66.4 4.1 mix NoGo
c - → - ↓ 
Pulvermüller et 
al. (1996) 
18 14 on 2.2 - 60.6 8.3 no 
all trials - - - ↓ 
Go - - - ↓ 
NoGo - - - ↓ 
Note. dem = demented; dur = disease duration in years; HC = healthy controls; HY = mean score obtained on the Hoehn & Yahr scale; 
med = antiparkinsonian medication state; mix = mixed; PD = patients with Parkinson’s disease; UPDRS = mean score obtained on Part 
III of the Unified Parkinson’s Disease Rating Scale; all trials = main effect of group (PD vs HC) obtained irrespective of the Go/NoGo 
condition; Go = group effect observed on Go-trials; NoGo = group effect observed on NoGo-trials; NoGo – Go = group effect observed 
on NoGo-minus-Go trials; ↑ indicates larger values of the respective measure in PD; ↓ indicates smaller values of the respective measure 
in PD; → indicates that no significant difference was found in the respective measure between PD and HC; - indicates that the measure 
could not be extracted from the respective study. 
aBeste et al. (2009a) used two versions of the Go/NoGo task where imperative stimuli were either semantically compatible (comp; i.e. Go: 
‘PRESS’, NoGo: ‘STOP’) or incompatible (incomp; i.e. Go: ‘STOP’, NoGo: ‘PRESS’) with the task, respectively. 
bAccording to the text in Bokura et al. (2005). 
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cAccording to Osawa et al. (2005), “the amplitude of nogo N2 trended to be higher (p=0.08) in PD” (p. 342), but it remains unclear 
whether N2 amplitudes tended to be enhanced (i.e., numerically more negative) or attenuated (i.e., numerically more positive) in PD 
patients. 
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Table 4 
Overview of the studies investigating N2 and P3 measures using interference tasks in patients with Parkinson’s disease. 
Study 
N 
HY UPDRS age dur dem task 
N2 P3 
PD HC latency amplitude latency amplitude 
on antiparkinsonian medication 
Rustamov et al. (2013) 20 20 2.0 15.1 59.0 5.4 no flanker 
incong: 
→ 
CSE: → 
CE: → 
CSE: ↓ 
- - 
Stemmer et al. (2007) 
on medication 
9 14 2.6 21.3 63.4 6.7 - flanker - cong: → - cong: → 
Verleger et al. (2010) 
on medication 
12 13 2.1 19.3 64.9 4.1 no flanker - 
incong: 
→ 
- - 
Willemssen et al. (2011) 
on medication 
20 32 - 10.8 64.5 3.2 - flanker → → → → 
Willemssen et al. (2011) 
de novo | post medication 
15 32 - 8.7 59.6 - - flanker → 
→ 
CE: → 
→ → 
off antiparkinsonian medication 
Praamstra & Plat (2001) 8 8 2.4 37.3 57.8 5.8 - Simon - → – ↓ - - 
Praamstra et al. (1998) 7 7 2.4 31.0 58.4 5.4 - flanker → → → → 
Willemssen et al. (2011) 
off medication 
20 32 - 14.8 64.5 3.2 - flanker → → → → 
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drug-naive 
Stemmer et al. (2007) 
de novo 
9 14 2.1 22.7 64.2 2.2 - flanker - cong: → - cong: → 
Verleger et al. (2010) 
mutation carriers 
19 13 0.5 - 41 - no flanker - incong: ↓ - - 
Willemssen et al. (2011) 
de novo | pre medication 
15 32 - 12.7 59.6 - - flanker → 
→ 
CE: ↓ 
→ → 
Note. CE = congruency effect; cong = congruent trials; CSE = congruency sequence effect; dem = demented; dur = disease duration in 
years; HC = healthy controls; HY = mean score obtained on the Hoehn & Yahr scale; incong = incongruent trials; PD = patients with 
Parkinson’s disease; UPDRS = mean score obtained on Part III of the Unified Parkinson’s Disease Rating Scale; ↓ indicates smaller 
values of the respective measure in PD; → indicates that no significant difference was found in the respective measure between PD and 
HC; → – ↓ indicates that multiple analyses were reported, yielding either no significant difference (→) or smaller values of the respective 
measure in PD (↓); - indicates that the measure could not be extracted from the respective study. 
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Table 5 
Overview of the studies investigating electrophysiological measures of performance monitoring in patients with Parkinson’s disease. 
Study 
N 
HY UPDRS age dur dem task 
Ne/ERN Nc/CRN 
PD HC latency amplitude latency amplitude 
on antiparkinsonian medication 
Falkenstein et al. (2001) 13 13 - 25 61.1 - no flanker → ↓ → → 
Falkenstein et al. (2001) 13 13 - 25 61.1 - no Simon ↓ ↓ → → 
Falkenstein et al. (2001) 14 14 - 25 61.1 - no Go/NoGo → ↓ → → 
Ito & Kitagawa (2006) 17 15 2.1 - 64.1 6.1 no 
lexical 
decision  
→ ↓ → → 
Rustamov et al. (2014) 20 20 2.1 15.9 59.8 5.7 no flanker  - ↓ - - 
Stemmer et al. (2007) 
on 
9 14 2.6 21.3 63.4 6.7 - flanker - ↓ - - 
Verleger et al. (2013) 12 12 2.1 19.3 64.9 4.1 no flanker → → - - 
off antiparkinsonian medication 
Beste et al. (2009b) 
off 
17 17 - 15.9 66.8 - - flanker → ↓ → → 
Holroyd et al. (2002) 9 9 2.5 26.9 56.1 6.1 no flanker - → - - 
Willemssen et al. (2008) 18 18 - 14.8 66.3 3.2 - flanker - ↓ - → 
drug-naive 
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Beste et al. (2009b) 
de novo 
15 17 - 12.6 59.6 - - flanker → ↓ → → 
Stemmer et al. (2007) 
de novo 
9 14 2.1 22.7 64.2 2.2 - flanker - ↓ - - 
Willemssen et al. (2009) 14 14 - 12.5 59.6a - - flanker → ↓ → ↑ 
Note. dem = demented; dur = disease duration in years; HC = healthy controls; HY = mean score obtained on the Hoehn & Yahr scale; 
med = antiparkinsonian medication state; Nc/CRN = correct(-related) negativity; Ne/ERN = error(-related) negativity; PD = patients with 
Parkinson’s disease; UPDRS = mean score obtained on Part III of the Unified Parkinson’s Disease Rating Scale; ↑ indicates larger values 
of the respective measure in PD; ↓ indicates smaller values of the respective measure in PD; → indicates that no significant difference 
was found in the respective measure between PD and HC; - indicates that the measure could not be extracted from the respective study. 
aAccording to the text in Willemssen et al. (2009). 
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Table 6 
Overview of the main findings on cognitive ERPs in PD. 
ERP PD-related changes in comparison to healthy controls 
Classical cognitive ERPs  
 P3b 
good evidence for a sensitivity of P3b latency to PDD, with prolongation in demented, 
but not in non-demented PD patients 
 P3a 
preliminary evidence for a relation of P3a amplitude attenuation to disease duration in 
PD 
 mismatch negativity (MMN) 
preliminary evidence for a sensitivity of MMN amplitude to PDD, with attenuation in 
demented, but not in non-demented PD patients 
Cognitive ERP correlates of executive 
control 
 
 (conflict-)N2 
preliminary evidence for attenuation of N2 amplitudes in drug-naive PD patients and in 
pre-symptomatic mutation carriers 
preliminary evidence for attenuation of the contextual modulation of conflict-N2 
amplitude in PD patients 
 NoGo-P3 preliminary evidence for Nogo-P3 amplitude attenuation in (medicated) PD patients 
 error(-related) negativity (Ne/ERN) good evidence for Ne/ERN amplitude attenuation in PD patients 
Note. PDD = Parkinson’s disease dementia; PD = Parkinson’s disease 
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Figure captions 
Fig. 1. Standard paradigms for recording of event-related potentials. In the two-stimulus oddball 
task depicted here, participants have to respond to rare target stimuli (large circles) embedded in 
a series of frequent standard stimuli (small circles). In the three-stimulus oddball task, infrequent 
novel or complex stimuli (deviant shapes) are added to the oddball series. The Go/NoGo task 
requires participants to respond on Go-trials (e.g., green circles) while withholding responses on 
NoGo-trials (e.g., red circles). In the flanker task, the participant is required to respond to a 
central target stimulus which is flanked by either congruent or incongruent distractor stimuli. 
Fig. 2. Predictors of P3b latency prolongation in PD patients. Depicted is the proportion of 
studies that reported significantly prolonged P3b latencies in PD patients (when compared to 
healthy controls) as a function of sample and task characteristics. p-values are the result of chi-
square tests for independence. 
Fig. 3. Graphical summary of the key results of this review. Left: The latency of the P3b 
waveform, elicited by rare target stimuli, has been found to be prolonged in patients with 
Parkinson’s disease (PD) dementia, but not in non-demented PD patients. Right: ERP markers of 
executive functioning (including the error(-related) negativity, Ne/ERN) have been shown to be 
altered in non-demented PD patients. Here, the amplitude of the Ne/ERN, elicited by erroneous 
responses, is attenuated in PD patients compared to healthy controls. 
Fig. 4. A. An illustration of the hypothesized inverted U-shaped relationship between dopamine 
levels (major effect of disease: severe dopamine depletion in the dorsal striatum; proposed effect 
of dopaminergic treatment: dopamine overdosing in the ventral striatum and/or the prefrontal 
cortex) and absolute values of ERP amplitudes. Table 3 shows that the NoGo-P3 data are 
compatible with optimal (i.e., corresponding – by definition – to those of age-stratified healthy 
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controls) amplitude values in PD patients who are off dopaminergic medication (one study) and 
attenuated amplitude values in PD patients who are on dopaminergic medication (four studies; 
shown in red). Table 5 shows that several Ne/ERN studies in PD patients yielded attenuated 
Ne/ERN amplitudes in PD patients who are off dopaminergic medication (two out of three 
studies) as well as attenuated amplitude values in PD patients who are on dopaminergic 
medication (six out of seven studies; shown in blue). B. The reviewed evidence leads to testable 
predictions for intra-individual ERP studies. Specifically, NoGo-P3 data in PD patients who are 
off dopaminergic medication should show amplitude values similar to those of healthy controls 
(i.e., age-stratified optimal values) and attenuated amplitude values in these PD patients when 
they are on dopaminergic medication (shown in red). Attenuated Ne/ERN amplitudes are 
expected in PD patients irrespective of dopaminergic medication (shown in blue). 
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Fig. 1. 
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Fig. 2.
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Fig. 3.
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Fig. 4. 
 
